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Abstract 
Proteinase-activated receptors (PARs) are a novel group of G-protein coupled receptors 
(GPCRs). The most striking evidence to distinguish them from other GPCRs is that 
they carry their own tethered ligand within extracellular N-terminus. To activate the 
receptors, the tethered ligand is exposed by proteolytic cleavage which subsequently 
binds to the extracellular loop 2 to trigger receptor function. Four members have been 
identified so far in this group—PAR1, PAR2, PAR3 and PAR4.  
 
Palmitoylation is the reversible covalent attachment of fatty acids to the cysteine 
residues of some GPCRs via a thioester linkage; resulting in a fourth intracellular loop. 
Although recent evidence has suggested that palmitoylation can have a profound effect 
on GPCR function such as cell surface expression and receptor signalling, the role of 
palmitoylation in regulating PAR function is currently unknown. This study focused on 
the role of putative palmitoylation region of hPAR1--C-terminal cysteines (C387and 
C388) in regulating receptor function.  
 
Wild type hPAR1 (wt-hPAR1) and hPAR1 mutants (hPAR1C387A, hPAR1C388A and 
hPAR1C387AC388A) were constructed and permanently expressed in Kirsten virus 
sarcoma transformed rat kidney epithelial cells (KNRK). hPAR1C387A and 
hPAR1C388A displayed similar cell surface expression (~80%) to that of wt-hPAR1, 
but hPAR1C387AC388A displayed only ~40% cell surface expression. hPAR1C387A, 
hPAR1C388A and wt-hPAR1 displayed similar sensitivity in calcium signalling 
towards selective PAR1 agonists—thrombin and TFLLR-NH2. Surprisingly, 
hPAR1C387AC388A failed to generate a calcium signal to either PAR1 agonists. The 
reduced cell surface expression of hPAR1C387A388A was not responsible for the lack 
of calcium signal since a wt-hPAR1 cell line with similar cell surface expression to 
hPAR1C387AC388A displayed robust responses to both thrombin and TFLLR-NH2. 
hPAR1C387AC388A was also unable to trigger ERK1/2 phosphorylation in response 
to either PAR1 agonists. In agonist triggered internalisation experiments all mutant 
receptors internalised in response to thrombin and TFLLR, except for wt-hPAR1 which 
only internalised in response to thrombin. Therefore, we conclude that putative 
palmitoylation sites within hPAR1 regulate receptor expression, agonist triggered 
internalisation and are critical for hPAR1 coupling to calcium and ERK1/2. 
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1. Introduction 
1.1 G-protein coupled receptors 
G-protein coupled receptors (GPCRs) constitute the largest family of cell surface 
receptors comprising approximately 3% of the human genome (Ostrom and Insel, 
2004). More than 800 human GPCRs have been identified since the first GPCR was 
cloned in 1986 (Ostrom and Insel, 2004, Gether, 2000, Oldham and Hamm, 2008). 
GPCRs are characterised as seven transmembrane spanning proteins with an 
extracellular N-terminus and a cytoplasmic C-terminus. They transmit a diverse range 
of extracellular signals into eukaryotic cells mainly by activating heterotrimetic 
guanine nucleotide binding proteins, which contain a guanosine diphosphate (GDP) 
bound α subunit and an inseparable complex of β and γ subunits (Gether, 2000, 
Oldham and Hamm, 2008). Signal transduction begins with the binding of an 
extracellular ligand to the receptor, the activated receptor then couples to a G protein, 
resulting in the exchange of GDP to GTP and subsequently the dissociation between α 
subunit and the βγ complex (Gether, 2000, Oldham and Hamm, 2008). Both α subunit 
and βγ complex in turn are able to regulate a wide variety of downstream effectors 
(Ostrom and Insel, 2004, Gether, 2000, Oldham and Hamm, 2008). 
Based on phylogenetic analysis, GPCRs existing in humans are grouped into five 
major classes, named rhodopsin, secretin, glutamate, adhension and frizzled/taste2 
(Oldham and Hamm, 2008, Fredriksson et al., 2003). 
The secretin family consists of a variety of receptors for peptide hormones and 
neuropeptides (Gether, 2000). They are characterized by a 60~80 amino acid long 
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N-terminus containing conserved cysteine bridges (Gether, 2000, Fredriksson et al., 
2003). The adhesion receptors were first termed as a group of the secretin family due 
to their structural similarities (Foord et al., 2005). Recently, the phylogenetic analysis 
by Fredriksson et al indicated a clear distinction between them, and thus adhension 
receptors are classified as an independent class, distinct from the secretin family 
(Fredriksson et al., 2003). The main characteristic of the adhesion family is their long 
N termini that contain adhesion-like motifs, such as epidermal growth factor-like and 
mucin-like repeats (Fredriksson et al., 2003, Yona et al., 2008). Members of the 
glutamate family have a so-called ‘Venus flytrap’ N terminus, which is composed of 
two lobes separated by a cavity where ligands bind (Fredriksson et al., 2003, Oldham 
and Hamm, 2008). The Frizzled/Taste2 family includes two distinct clusters the 
frizzled receptors and the taste2 recetors (Fredriksson et al., 2003). Frizzled receptors 
respond to signals from secreted glycoproteins termed Wnt and their 200 amino acid 
long N-termini with conserved cysteines are believed to participate in Wnt binding 
(Fredriksson et al., 2003). Taste2 receptors share several consensus sequences with 
frizzled receptors, but have a very short N terminus that is unlikely to contain a ligand 
binding site (Fredriksson et al., 2003). 
The rhodopsin family, also called class A, is the largest group of GPCRs and the most 
studied (Fredriksson et al., 2003, Gether, 2000). The most distinct feature 
differentiating the rhodopsin family from other families is their short N-termini 
(Fredriksson et al., 2003). The overall homology among all the receptors in this family 
is low, but they still have several highly conserved residues such as a DRY motif at the 
cytoplasmic side of transmembrane domain 3, and an NSxxNPxxY motif in 
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transmembrane domain 7 (Fredriksson et al., 2003, Gether, 2000, Oldham and Hamm, 
2008). Moreover, most of the rhodopsin family receptors contain a disulfide bridge 
connecting the second and third extracellular loop, and a putative palmitoylation site in 
the C-terminus (Gether, 2000).  
The rhodopsin family receptors respond to diverse types of ligands, and thus have 
different modes in ligand binding (Gether, 2000, Oldham and Hamm, 2008). For 
example, amine neurotransmitters are activated by ligand binding within the crevice 
formed by transmembrane domains, whereas glycoprotein hormones such as follicle 
stimulating hormone, luteinizing hormone and thyroid stimulating hormone activate 
the receptors by initially binding to the extracellular N-terminus, leading to a liganded 
N-terminal segment which makes a secondary contact with the extracellular loops 
(Gether, 2000). 
 
1.2 Proteinase-activated receptors 
Proteinase-activated receptors (PARs) are a novel group of the rhodopsin family of 
GPCRs. They have the typical GPCR structure: seven transmembrane domains, three 
intracellular loops, three extracellular loops, an extracellular N-terminus and an 
intracellular C-terminal tail. However, PARs are characterised by a distinctive 
mechanism of activation. They carry their own ligand in the extracellular N-terminus 
instead of requiring exogenous ligand binding. Proteolytic cleavage of the N-terminal 
of PARs releases a tethered ligand sequence which can activate the receptors to initiate 
signalling. Four members of PARs have been identified in humans so far--PAR1, PAR2 
PAR3, and PAR4.  
  5
1.2.1 Cloning of PARs 
1.2.1.1 PAR1 
Thrombin has been recognized as a key effector proteinase in the coagulation process 
for a number of decades. It was originally identified as a trypsin-like serine proteinase 
which converts the soluble fibrinogen into insoluble strands of fibrin in the 
bloodstream, and produced through the proteolytic activation of prothrombin by the 
action of factor Xa (Davie et al., 1991, Stubbs and Bode, 1993). Tissue factor, an 
integral membrane protein, is the initiating factor in the coagulation cascade, is 
expressed by the cell types that under normal condition do not access the bloodstream 
(Drake et al., 1989). Disruption of vascular integrity allows circulating coagulation 
factors to contact extravascular tissue factor, and then trigger thrombin generation 
(Coughlin, 2005). Thrombin was thus identified as a component of a coagulation 
process linking tissue damage to wound repair (Coughlin, 2005). Thrombin is also 
found to be perhaps the most potent physiologic activator of platelet aggregation, and 
thrombin-induced platelet aggregation is critical for hemostasis and thrombosis 
(Berndt et al., 1986, Eidt et al., 1988).  In addition, several studies suggested that 
thrombin was a potent agonist for a number of biological responses, and had direct 
cellular effects on various cell types such as monocytes, smooth muscle cells or 
endothelial cells (Bar-Shavit et al., 1983, Bizios et al., 1986). These observations led to 
the search for a thrombin receptor. Although classical radioligand binding studies with 
modified thrombin had identified several candidate throumbin-binding proteins, no 
functional thrombin receptors had been identified until 1991 (Gronke et al., 1987).  
In 1991, the first functional thrombin receptor, which subsequently termed as PAR1, 
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was identified by two laboratories. Vu et al expressed mRNA isolated from human 
thrombin responsive megakaryocytic HEL and Dami cells in Xenopus oocytes, and 
then identified a functional clone using a size-selected cDNA library (Vu et al., 1991a). 
The other group cloned the thrombin receptor from CCL39 hamster lung fibroblasts by 
selective PCR amplification of mRNA sequences that displayed homology to the 
transmembrane domains of GPCR (Rasmussen et al., 1991, Vu et al., 1991a). The 
study by Vu et al (1991) revealed the cDNA sequence encoded a 425 amino acid 
protein, and the hydropathy analysis revealed the protein included an amino-terminal 
signal sequence and seven hydrophobic transmembrane domains of a typical GPCR 
(Vu et al., 1991a). A potential thrombin cleavage site (LDPR41↓S42FLLRN, where ↓ is 
the cleavage site) was identified within the 75 amino acid long N-terminus, and the 
first six residues of newly created amino terminus SFLLRN would mediate the 
receptor activation (Vu et al., 1991a). Moreover, genomic analysis indicated that the 
human PAR1 (hPAR1) gene was localised to region q13 of chromosome 5 and 
consisted of two exons separated by a 22kb intron (Bahou et al., 1993b, Schmidt et al., 
1996). The majority of the protein including the thrombin cleavage site is encoded in 
the larger second exon (Schmidt et al., 1996).  
 
1.2.1.2 PAR2 
PAR2 was first identified in 1994 by screening a mouse genomic library with a mixture 
of two oligonucleotide primers corresponding to transmembrane regions of the bovine 
substance K receptor (Nystedt et al., 1994, Nystedt et al., 1995b) Subsequently, the 
human PAR2 (hPAR2) was cloned in the next year by the same group (Nystedt et al., 
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1995). The deduced hPAR2 sequence revealed that the protein was 397 amino acids 
long and 83% similar to the mouse PAR2 with many conservative substitutions 
(Nystedt et al., 1995, Bohm et al., 1996b). The putative cleavage sites 
(SKGR34↓S35LIG) for both receptors were conserved, however, the exposed tethered 
ligands were different (SLIGKV in human and SLIGRL in mice) (Nystedt et al., 1994, 
Bohm et al., 1996b). The first four residues are identical but the lysine and valine 
residues at position 5 and 6 in the tether ligand of hPAR2 have been replaced by 
arginine and leucine residues in mPAR2 (Bohm et al., 1996b, Nystedt et al., 1995). 
Similar to the organization of hPAR1, the hPAR2 gene is divided into two exons with 
the cleavage site encoded in the larger second exon, and is also mapped to 
chromosomal region 5q13, where the hPAR1 receptor was previously shown to be 
located (Nystedt et al., 1995). 
 
1.2.1.3 PAR3 
In PAR1 knockout mice, the platelets remained responsive to thrombin whereas 
thrombin responses were not detectable in the fibroblasts (Connolly et al., 1996). The 
evidence strongly suggested the existence of a second thrombin receptor in mouse 
platelets (Connolly et al., 1996). cDNA of a new thrombin receptor designated PAR3, 
was then yielded from human and mice using a PCR based strategy in 1997 (Ishihara 
et al., 1997). The deduced hPAR3 protein sequence is 374 amino acids long with a 27% 
sequence homology to hPAR1 and a 28% sequence homology to hPAR2 (Ishihara et al., 
1997). The thrombin cleavage site of hPAR3 is located at TLPIK38T39FRGAP with a 
thrombin-binding site (S47FEEFP52) immediately downstream in the N-terminus 
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(Ishihara et al., 1997). Genomic analysis identified that the hPAR3 gene, like hPAR1 
and hPAR2, displayed a two-exon structure in which the second exon contained the 
majority of the protein and the cleavage site, additionally, the hPAR3 gene was located 
to the same hPAR gene cluster at 5q13 as hPAR1 and hPAR2 (Schmidt et al., 1998). 
 
1.2.1.4 PAR4 
Studies in platelets from PAR1 and PAR3 deficient mice suggested the existence of yet 
another thrombin receptor (Connolly et al., 1996, Kahn et al., 1998). PAR4 as a fourth 
member of the PAR family was identified by searching an expressed sequence tag 
database by two separate laboratories (Xu et al., 1998, Kahn et al., 1998). The protein 
consists of 385 amino acids with a proteinase cleavage site (PAPR47G48YPGQV) in 
the N-terminus (Xu et al., 1998). PAR4 shares 33% sequence identity with the other 
PAR family members, but its extracelluar N-terminus and intracellular C-terminus 
have little or no sequence similarity to the corresponding regions of the other hPARs 
(Xu et al., 1998). When expressed in Xenopus oocyte, or COS cells, PAR4 was 
responsive to thrombin, but the activation required higher thrombin concentrations 
than PAR1 and PAR3 (Xu et al., 1998). This is probably due to the absence of the 
highly acidic thrombin-binding site observed in the N-terminus of PAR1 and PAR3 (Xu 
et al., 1998). The PAR4 gene chromosomal localisation was identified as 19p12 (Xu et 
al., 1998). This location was different from the PAR gene cluster located at 
chromosome 5q13 and suggested differences in the evolutionary development of PAR4 
(Xu et al., 1998). 
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1.2.2 Mechanism of activation 
Unlike other GPCRs, PARs contain their own ligand within the extracellular 
N-terminus. Proteinases cleave PARs at a specific enzymatic site in the extracellular 
N-terminus; the unmasking of new N-terminal residues serves as a tethered ligand and 
binds to the extracellular domain 2 and subsequently triggers receptor function (Fig 1.1) 
(Hollenberg and Compton, 2002, Dery et al., 1998, Macfarlane et al., 2001). In 
addition, it is found that with the exception of PAR3, the short synthetic peptides, (only 
five or six animo acids in length) derived from the tethered ligand sequences can also 
activate the receptors without proteolytic cleavage by direct binding to the extracellular 
loop 2 (Fig 1.1) (Hollenberg and Compton, 2002, Dery et al., 1998, Macfarlane et al., 
2001). These peptides are so-called PAR-activating peptides (PAR-APs). However, 
PAR-APs show lower potency than proteinases in receptor activation. This may be due 
to the inefficient presentation of these peptides to the binding domain of the receptor in 
comparison to the tethered ligand (Ossovskaya and Bunnett, 2004, Blackhart et al., 
2000). 
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Figure 1.1, PAR activation mechanism by tethered ligands and synthetic agonist 
peptides. 
 
 
1.2.2.1 PAR1 
The mechanism of activation of PAR1 has been extensively investigated and well 
defined. PAR1 is activated by thrombin and contains a thrombin cleavage recognition 
and cleavage site (LDPR41↓S42FLLRN) in the N-terminal domain. Immediately 
following the cleavage site, there is a highly acidic domain (D51KYEPFWEDEE) 
resembling a thrombin binding site in the leech anticoagulant hirudin, which can 
effectively bind to thrombin’s anion-binding exosite (Vu et al., 1991a), and thus this 
domain is a so-called hirudin-like site. The importance of the thrombin cleavage 
recognition sequence was indicated by domain swap experiments in which the amino 
acids LDPR were replaced with the sequence DDDK, the recognition site for the 
Proteinase 
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proteinase enterokinase (Vu et al., 1991b). The resulting PAR1 mutant completely 
switched the receptor specificity, abolished thrombin responses and responded to 
enterokinase (Vu et al., 1991b). Further experiments using antibodies blocking the 
thrombin cleavage site also abolished the receptor activation (Bahou et al., 1993a, 
Chen et al., 1994). The deletion of the hirudin-like site in PAR1 reduced the capacity of 
thrombin to activate PAR1, whereas substitution of this domain with the corresponding 
hirudin C-terminal thrombin binding domain restored the full ability of thrombin to 
activate PAR1 (Vu et al., 1991b). Moreover, γ-thrombin lacking the anion-binding 
exosite is 100-fold less potent than thrombin in PAR1 activation (Bouton et al., 1995). 
This site is essential for high affinity binding and activating potency of thrombin 
towards PAR1. Therefore, it suggested that thrombin interacts with PAR1 through the 
recognition sequence LDPR/S and hirudin-like sequence DKYEPFWEDEE, and then 
cleaves the receptor at the Arg-Ser peptide bond to activate the receptor. To investigate 
the interaction between the tethered ligand and the body of the receptor, substitution of 
Xenopus PAR1 receptor with cognate human receptor sequence suggested that two 
regions contritubed to the tethered ligand binding specificity: residues 82-90 in the 
amino-terminal and residues 259-262 in the second extracellular loop (ECL2) 
(Nanevicz et al., 1995). In addition, the transmembrane 7th helix and 8th helix in the 
C-terminal domain anchored by the 7th transmembrane helix and putative 
palmitoylation sites have been indicated to be critical in activation of Gq signalling, 
and this result supported a 7-8-1 receptor activation mechanism for PAR1 activation of 
Gq, whereby the 8th helix interacts with transmembrane domain 7 and intracellular 
loop 1 during signal transference from receptors to G proteins (Swift et al., 2006).  
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The short synthetic peptide corresponding to the hPAR1 tethered ligand, SFLLR can 
activate PAR1 without proteolytical cleavage. However, SFLLR was also shown to have 
a cross-activation with hPAR2 (Blackhart et al., 1996). Substitution of the first serine 
residue with a threonine residue made TFLLR highly specific to PAR1 (Hollenberg et 
al., 1997), indicating that Phe2, Leu4 and Arg5 are important residues for full PAR1 
activation (Scarborough et al., 1992). Further, a series of PAR1-APs have been 
synthesized with enhanced agonist potencies. For example, a designed peptide 
Ala-(pF)Phe-Arg-Cha-hArg-Tyr-NH2 shows 1000-fold higher agonist potency than 
SFLLR (Feng et al., 1995). However, although PAR1-AP can elicit full response from 
PAR1, it does not mimic the activation of the receptor by thrombin in all respects 
(Blackhart et al., 2000). Studies have shown that there are profound differences in the 
activation mechanism of PAR1 by the tethered ligand and free peptide (Blackhart et al., 
2000). Mutations capable of virtually eliminating a response to the PAR1-AP have little 
effect on the activation of the receptor by thrombin. For example, the deletion mutant 
lacking amino acids 68-93 of the N-termini has completely lost the ability to respond to 
PAR1-AP yet still retains the ability to generate a maximal response to thrombin at a 
10-fold higher concentration. PAR1 also shows the functional selectivity of G protein 
signalling by thrombin and PAR1-APs (McLaughlin et al., 2005). Compared with 
stimulation by thrombin, peptide induced activation alters PAR1-G protein coupling to 
favor Gq binding over G12/13 in human microvascular cells (McLaughlin et al., 2005).  
There is evidence that PAR1 activation can be intermolecular between adjacent PAR1 
receptors, and intramolecular liganding is the dominant mode of thrombin receptor 
activation (Chen et al., 1994). Coexpression of a PAR1 mutant lacking a functional 
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tethered ligand domain with PAR1 mutant that contained a functional tethered ligand 
but unable to signal, still resulted in thrombin signalling (Chen et al., 1994).  
 
1.2.2.2 PAR2  
PAR2 was identified as a trypsin receptor and can be activated by trypsin cleavage at 
SKGR34↓S35LIG in the N-terminal domain (Bohm et al., 1996b, Lerner et al., 1996, 
Nystedt et al., 1994, Bohm et al., 1996a). Similar to PAR1, the ECL2 of PAR2 was 
shown to be a critical determinant for PAR2 responsiveness to the tethered ligand. A 
PAR1-PAR2 chimera in which the ECL2 of PAR1 was replaced by the cognate segment 
of PAR2 gained more than 10-fold responsiveness to PAR2 peptide (Lerner et al., 1996). 
This study also revealed that extracellular N-terminus and ECL3 participate in agonist 
recognition. Moreover, Al-Ani et al indicated that the first tethered ligand dipeptide 
S35L and the acidic tripeptide P231EE in ECL2 perform an important role in PAR2 
activation (Al-Ani et al., 1999, Al-Ani et al., 2004).  
In contrast to PAR1, where thrombin attaches to the hirudin-like domain of the receptor 
during the activation, there is no evidence to suggest that proteinases interact with 
PAR2 at sites other than the cleavage site. The synthetic peptide corresponding to the 
tethered ligand (SLIGRL in mouse, SLIGKV in human) activates PAR2 by the same 
ligand mechanism as PAR1 (Bohm et al., 1996b, Nystedt et al., 1994). The hPAR2-AP 
SLIGKV is very specific but has a relatively low potency, interestingly the mPAR2-AP 
SLIGRL is shown to be a higher potency agonist for hPAR2 than the native peptide 
(Blackhart et al., 1996). Recently, several synthetic pepetides have been designed for 
PAR2 with a high degree of agonist potency (Maryanoff et al., 2001, Kawabata et al., 
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2004a, McGuire et al., 2004, Kanke et al., 2005, Seitzberg et al., 2008). 
PAR2 can also be transactivated by cleaved PAR1 intermolecularly (O'Brien et al., 
2000). O’Brien and colleagues showed that the cleaved PAR1 can donate its tethered 
ligand to PAR2 and transactive PAR2 under the conditions in which PAR1 has a 
mutation in the second extracellular loop and thus can not signal (O'Brien et al., 2000). 
This may explain why PAR1-AP is able to activate PAR2, while PAR2-AP failed to 
activate PAR1 (Blackhart et al., 1996).  
 
1.2.2.3 PAR3  
PAR3 the second thrombin receptor was revealed to have a number of structural and 
functional similarities to PAR1. Its N-terminus contains a hirudin-like domain (FEEP) 
and a thrombin cleavage site LPIK38T39FRG (Ishihara et al., 1997). Both mutation of 
thrombin cleavage site and mutation of hirudin-like domain prevent receptor cleavage 
by thrombin (Ishihara et al., 1997). After cleavage by thrombin, the exposed amino 
terminus is presumed to interact with the receptor as a tethered ligand (Ishihara et al., 
1997). However, the synthetic peptide representing the tethered ligand sequence of 
PAR3 failed to activate PAR3 but was shown to activate PAR1 and PAR2 instead 
(Ishihara et al., 1997, Hansen et al., 2004, Kaufmann et al., 2005). Curiously, mPAR3 
itself is unable to mediate transmembrane signalling even when overexpressed, but 
instead functions as a cofactor for mPAR4 activation by thrombin (Nakanishi-Matsui et 
al., 2000).  
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1.2.2.4 PAR4  
Both thrombin and trypsin cleave PAR4 at the N-terminal site PAPR47G48YPGQV and 
unmask a new amino terminus which serves as a tethered ligand to activate the receptor 
(Xu et al., 1998). Mutation of the cleavage site results in a receptor that is unresponsive 
to proteinases (Xu et al., 1998). PAR4 lacks the hirudin-like site, and is therefore less 
responsive to thrombin in comparison to PAR1 (Xu et al., 1998). However, it has been 
reported that PAR4 uses anionic residues (Asp57, Asp59, Glu62 and Asp65) in the 
exodomain to extend contacts with thrombin during activation (Nieman, 2008). The 
mutation of all the four anionic residues resulted in a receptor which responded to 
thrombin with a 6-fold higher EC50 value compared to the wild type PAR4, Asp59 having 
the greatest influence (Nieman, 2008). The synthetic peptides based on the 
proteolytically tethered ligand sequence (GYPGQV in human, GYPGKF in mouse) can 
fully activate the receptor (Xu et al., 1998). Nonetheless like PAR1, the hPAR4-AP, 
GYPGKF, is less efficient than thrombin at activating PAR4, the analogy AYPGKF has 
been developed with ~10 fold greater potency than GYPGKF and also relatively 
specific for PAR4 (Faruqi et al., 2000).  
 
1.2.2.5 Receptor dimerisation  
The ligand-activated G-protein coupled receptors are initially considered as monomers 
that interact with their specific G proteins (Bulenger et al., 2005). However, more and 
more evidence is suggesting many GPCRs are capable of forming and functioning 
within dimers or larger oligometric complexes (Bulenger et al., 2005). A significant 
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finding was the metaboryopic GABAB receptor which exists as an obligatory 
heterodimer (Marshall et al., 1999). Although it was first believed to be an exception, a 
large number of resonance energy transfer-base studies subsequently showed that 
GPCRs could form both homo and hetero-dimers in living cells. Receptor dimerisation 
has been shown to modulate GPCRs function such as signalling, trafficking, 
internalisation and desensitisation.  
Recently, a nuclear magnetic resonance structure of the thrombin-cleaved PAR1 
exodomain displays that PAR1 bound to anion-binding exosite of thrombin leaves the 
active site of thrombin still capable of interacting with other large macromolecules 
such as PAR4 (Seeley et al., 2003). PAR3 has been shown to act as a high affinity 
thrombin binder for adjacent PAR4 in mouse platelets (Nakanishi-Matsui et al., 2000). 
These observations suggest the existence of PAR dimerisation. A study using 
coimmunoprecipitation and flurorescence resonance energy transfer has shown that 
PAR1 and PAR4 formed a heterodimer in human platelets and fibroblasts, and 
coexpression of PAR1 with PAR4 enhanced PAR4 cleavage and activation (Leger et al., 
2006). Furthermore, PAR3 has been demonstrated to form heterodimers with PAR1 
affecting PAR1/G13 coupling in endothelial cells and thus regulates PAR1 signalling 
(McLaughlin et al., 2007). 
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Figure 1.2 Summary of domains thought to be important in PAR signalling. 
Adapted from (Macfarlane et al., 2001, Ossovskaya and Bunnett, 2004) 
 
 
 
Extracellular 
Intracellular 
N-terminus 
C-terminal tail 
Thrombin binding domain 
Tethered ligand 
Proteinase cleavage site 
Extracellular loop 2 
PAR1   ESKATNATLDPR  SFLLRN  PN DKYEPFWEDEEKNES
PAR2                                 
PAR3                                         
PAR4                                             
DGGTNRSSKGR SLIGKV
NDTNNLAKPTLPIK  TFRGAP  PNS FEEEP FSALE 
LPAPR GYPGQV CANDSDTLELPDSS PAR1 QTIQVPGLNITTCHDVLNETLLEG 
PAR2 QTIFIPALNITTCHDVLPEQLLVG 
PAR3 QEYYLVQPDITTCHDVHNTCESS 
PAR4 QTFRLARSDRVLCHDALPLDAQAS
PAR1 SECQRYVYSILCCKESSDPSSYNSSGQLMASKMDTCSSNLNNSOYKKLLT
PAR2 SHDFRDHAKNALLCRSVRTVKQMQVSLTSKKHSRKSSSYSSSSTTVKTSY
PAR3 SKTRNHSTAYLTK  
PAR4 SAEFRDKVRAGLFQRSPGDTVASKASAEGGSRGMGTHSSLLQ 
  18
1.2.3 PAR mediated intracellular signalling 
As described above, Mammalian G proteins are membrane-bound heterotrimeric 
proteins that receive signals from GPCRs and then transduce signals to intracellular 
effectors. They are made up of α, β and γ subunits, and are divided into four classes 
based on the sequence of the Gα subunit—Gs, Gi/o, Gq/11 and G12/13 (Oldham and 
Hamm, 2008, Wettschureck and Offermanns, 2005). The different downstream 
effectors activated by Gα are dependent on Gα subtype, for example, Gs α subunits 
activate adenylyl cyclase, Gi/o α subunits inhibit adenylyl cyclase and Gq/11 α subunits 
activate phospholipase C (Cabrera-Vera et al., 2003). Most GPCRs can activate more 
than one G protein subtype, and thus the activation of a single GPCR can trigger 
several signal transduction pathways. One downstream pathway of G proteins is the 
activation of phospholipase C (PLC), resulting in the phosphatidylinositol 
4,5-bisphosphate (PIP2) hydrolysis and the formation of inositol triphosphate (IP3) and 
diacylglycerol (DAG), IP3 in turn mediates the calcium release from endoplasmic 
reticulum, while DAG activates protein kinase C (PKC) (Cabrera-Vera et al., 2003).  
Activation of G proteins can also activate the mitogen-activated protein kinase (MAPK) 
pathway. The activation of MAPK occurs through the sequential phosphorylation 
cascade; at least two upstream kinases are required--mitogen-activated protein kinase 
kinase kinase (MAPKKK or MEKK) and mitogen-activated protein kinase kinase 
(MAPKK, MKK or MEK) (Krishna and Narang, 2008, Chang and Karin, 2001). In 
mammals, six distinct MAPK groups have been reported, extracellular signal-related 
kinases (ERK1/2), Jun amino-terminal kinases (JNK1/2/3), p38 proteins ERK7/8, 
ERK3/4 and ERK5 (Krishna and Narang, 2008). Each group is activated by specific 
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MAPKKs such as ERK1/2 which is activated by MEK1/2, ERK5 is activated by 
MEK5 and p38 is activated by MKK3/6, however, each MAPKK is able to be 
phosphorlyated by more than one MAPKKK that enhances the complexity and 
diversity of MAPK signalling system (Chang and Karin, 2001). 
 
Figure 1.3, An outline of GPCR signalling pathways. Activated GPCR can couple to 
different G protein subtypes and trigger different signalling pathways. cAMP, cyclic 
adenosine monophosphate; PKA, protein kinase A; RhoGEF, Rho guanine nucleotide 
exchange factor; PLC, phospholipase C; DAG, diacylglycerol; IP3, inositol 
triphosphate; PKC, protein kinase C.  
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1.2.3.1 PAR1 
PAR1 is shown to couple with multiple G proteins, including members of Gi/o, Gq/11 and 
G12/13 families (Macfarlane et al., 2001, Steinhoff et al., 2005). 
The PAR1 interaction with Gi proteins, resulting in the inhibition of adenylyl cyclase 
and formation of cAMP have been reported in multiple cell types such as HEL cells 
(Brass et al., 1991), osteosarocoma cells (Babich et al., 1990), vascular smooth muscle 
cells (Kanthou et al., 1996), fibroblasts (Hung et al., 1992a), platelets (Kim et al., 2002), 
astrocytes (Wang et al., 2002), endothelial cells (Vanhauwe et al., 2002) and olfactory 
sensory neurons (Olianas et al., 2007). Coupling of PAR1 to Gq/11, leading to the 
activation of PLC and calcium mobilization was revealed through the use of G protein 
specific antibodies inhibiting PAR1 mediated calcium signalling in CCL-39 fibroblast 
cells and through co-immunoprecipitation of Gq/11 with PAR1 (Baffy et al., 1994, Ogino 
et al., 1996). Further evidence for PAR1 interaction with Gq/11 has been reported in 
astrocytes and olfactory sensory neurons (Wang et al., 2002, LaMorte et al., 1993). 
Studies also show that PAR1 couples to G12/13 in thrombin stimulated platelets and 
couples to G12 in astrocytoma cells (Offermanns et al., 1994, Post et al., 1996, Aragay et 
al., 1995). PAR1 is also shown to activate multiple downstream signalling pathways 
including ERK1/2 MAPK via activation of PI-3 kinase (Malarkey et al., 1995) and Src 
family tyrosine kinases (Sabri et al., 2002, Darmoul et al., 2004). 
 
1.2.3.2 PAR2 
There is no direct evidence linking PAR2 to G protein activation, however, numerous 
  21
studies show that PAR2 activation leads to increased second messenger responses. 
Trypsin and PAR2-AP stimulate calcium mobilization in PAR2 transfected cell lines, 
suggesting that coupling and signalling through Gq/11 and possibly Gi/o (Macfarlane et 
al., 2001). Coupling of PAR2 with G12/13 has not been reported.  
 
1.2.3.3 PAR3 and PAR4 
PAR4 is reported to couple to Gq not Gi in platelets (Faruqi et al., 2000). The activation 
of PAR4 has been reported to result in calcium signalling (Kahn et al., 1998, Xu et al., 
1998, Camerer et al., 2002) and PAR4 activation in vascular smooth muscle cells 
stimulated MAPK signalling (Bretschneider et al., 2001). Additionally PAR4 mediated 
Src dependant p38 phosphorylation and activation of ERK and PLC has been 
demonstrated in PAR1 knockout mice derived cardiomyocytes (Sabri et al., 2003). 
 
1.2.4 Termination of signalling 
The activation of PARs is an irreversible proteolytic mechanism, the generated tethered 
ligand cannot diffuse away from the receptor, and thus activation would result in a 
prolonged signalling event. However, the signalling mediated by PARs is transient in 
nature, efficient mechanisms must exist for termination of PARs signalling (Trejo, 2003, 
Hollenberg and Compton, 2002). GPCR signalling is terminated by rapid 
phosphorylation of activated receptors by G protein receptor kinases and/or other 
kinases, followed by β-arrestin binding to GRK phosphoylated receptors, which disrupts 
the interaction between receptors and G proteins (Arora et al., 2007, Traynelis and Trejo, 
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2007). Subsequently, GPCR internalization occurs to remove activated receptor from G 
protein and signalling effectors at the plasma membrane. Studies on PARs have 
reported that sequences within the intracellular receptor domains and the C-terminal tail 
regulate receptor desensitisation and internalisation (Macfarlane et al., 2001; 
Hollenberg & Compton, 2002; Trejo, 2003).  
 
1.2.4.1 Desensitisation 
Activated PAR1 is desensitised by rapid phosphorylation at the carboxy terminus which 
is mediated by G protein receptor kinases (GRKs). GRK3 and GRK5 are shown to be 
two principal mediators in this phosphorylation. Overexpression of GRK3 in Xenpus 
oocytes enhanced PAR1 phosphorylation and blocked receptor mediated calcium 
signalling, whereas GRK2 is considerably less effective (Ishii et al., 1994). In vivo, 
studies in transgenic mice over expressing myocardial GRK3 have confirmed the 
importance of GRK3 in PAR1 desensitisation (Iaccarino et al., 1998). A separate study 
in endothelial cells showed that GRK5 overexpression markedly increased the 
phosphorylation of PAR1 (Tiruppathi et al., 2000). β-arrestins are also involved in 
PAR1 desensitisation through phosphorylating PAR1 C-terminal  tail, but they do not 
show the involvement in receptor internalisation (Paing et al., 2002). Desensitisation of 
PAR1 is markedly impaired in mouse embryonic fibroblasts lacking β-arrestin 1 and 
β-arrestin 2 (Paing et al., 2002). In addition, a recent study showed that β-arrestins 
were able to bind and desensitise the activated PAR1 independent of GRK 
phosphorylation at the C-terminus (Chen et al., 2004).  
Protein kinase C appears to be the primary mediator of PAR2 C-terminal 
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phosphorylation and desensitisation rather than GRK (Bohm et al., 1996a). 
Desensitisation and internalisation of activated PAR2 is shown to be dependent on 
β-arrestins but occur independently of the C-terminal tail (Stalheim et al., 2005, DeFea 
et al., 2000). There have been no studies in mechanisms of PAR3 desensitisation. The 
study in PAR4 has shown that PAR4 desensitises slower than PAR1 perhaps due to the 
lack of C-terminal phosphorylation sites (Shapiro et al., 2000). 
 
1.2.4.2 Internalisation 
Unlike most GPCRs, which are internalised, dephosphorylated and then return to the 
cell surface, PARs are internalised and directed to lysosomes for degradation. 
Activated PAR1 is internalised by a clathrin and dynamin dependent pathway to coated 
pits (Dery et al., 1998, Trejo, 2003). Dominant-negative dynamin and clathrin mutants 
both blocked PAR1 internalisation (Trejo et al., 2000). Phosphorylation at the 
C-terminus plays an important role in PAR1 internalisation. A receptor with alanine 
substitutions at all phosphorylation sites in the C-terminus failed to internalise 
(Hammes et al., 1999). Moreover, evidence revealed that PAR1 internalisation was 
independent of β-arrestin which play a critical role in internalisation of many GPCRs 
(Paing et al., 2002). Interestingly, uncleaved PAR1 in endothelial cells has been 
reported to cycle constitutively between the cell surface and the intracellular 
compartment (Paing et al, 2006). 
Like PAR1, internalisation of PAR2 is mediated by clathrin and dynamin, disruption or 
inhibition of clathrin function has been shown to affect receptor endocytosis (Dery et al., 
1999). Unlike PAR1, however, β-arrestins were revealed to play a critical role for PAR2 
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internalization. PAR2 internalization is completely abolished in cells lacking arrestins 
(Stalheim et al., 2005, Kumar et al., 2007). A mutant PAR2 which is unable to interact 
with β-arrestins failed to internalise (DeFea et al., 2000). Phosphorylation is an 
important mediator in PAR1 internalization, whereas mutations of potential 
phosphorylation sites in C-tail of PAR4 have no effect in receptor internalization 
(Shapiro et al, 2000). This may explain why agonist-induced internalization of PAR4 is 
much slower than that of PAR1. 
 
1.2.4.3 Disarming and amputation of tethered ligand by proteinase 
Some proteinases can disable PARs by cleaving and removing the tethered ligand so 
that the generated receptors are unresponsive to activating proteinases. Neutrophil 
enzymes such as cathepsin G, elastase and proteinase 3 can cleave PAR1 at distinct 
cleavage sites within the N-terminus and remove the tethered ligand domain, and 
thereby abolish the signalling to thrombin (Renesto et al., 1997, Molino et al., 1995). 
The amputated PAR1 is still responsive to PAR1AP suggesting that the binding domain 
in the second extracellular loop is preserved (Renesto et al., 1997). Chymase, a mast 
cell proteinase was also shown to inhibit thrombin signalling of keratinocytes 
(Schechter et al., 1998). Trypsin has also been reported to eliminate the response of 
PAR1 to thrombin in endothelial cells (Nakayama et al., 2003, Kawabata et al., 1999). 
However, studies in human embryonic kidney cells have revealed that trypsin activates 
PAR1 at a high concentration, but disarms PAR1 at a low concentration (0.5-10 nM) 
(Kawabata et al., 1999). Plasmin, a proteinase of the coagulation cascade, is also 
shown to activate and inactivate PAR1 depending on the concentration (Kuliopulos et 
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al., 1999).  
Elastase and cathepsin G have been revealed to disarm PAR2 by proteolysis of the 
extracellular domain downstream of the activation site, rendering the receptors 
unresponsive to the activating proteinases (Uehara et al., 2003). Cathepsin-G and 
elastase have also been shown to abolish thrombin signalling in PAR3 transfected cells 
(Cumashi et al., 2001).  
 
1.2.4.4 Recycling 
Due to the irreversible activation mechanism, most activated PARs are destined for 
lysosomal degradation. However, studies showed that a fraction of activated PAR1 
recycle back to the cell surface after internalisation (Hein et al., 1994). It was observed 
that more than 85% of PAR1 receptors on megakaryoblastic human erythroleukemia 
(HEL) were rapidly internalised after activation, and with approximately 25% of the 
internalised receptors returned to the cell surface (Hoxie et al., 1993). This observation 
was subsequently confirmed by using monoclonal antibodies with different epitopes 
(Brass et al., 1994). Over a three-hour period following thrombin stimulation, the cell 
surface receptors reacted with the antibodies recognizing the retained portions of the 
receptor N terminus, but not with the antibodies binding to the cleavage site of PAR1 
(Brass et al., 1994). Interestingly, the recycled receptors also failed to respond to 
thrombin and to self-activate, but remain responsive to PAR1-AP SFLLRN (Brass et al., 
1994). 
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1.3 Post-translational modification of GPCRs 
Following translation many proteins can undergo chemical modifications termed 
post-translational modifications. There are a number of different post-translational 
modifications such as phosphorylation, glycosylation, methylation and acylation. 
Palmitoylation is one of the most common post-translational lipid modifications in 
eukaryotic cells. It is the reversible covalent attachment of a 16-carbon saturated 
palmitic acid to one or more cysteine residues of the protein via a thioester linkage. 
GPCRs are also subject to this post-translational addition of palmitic acid, and it results 
in the formation of an additional (fourth) intracellular loop with the plasma membrane. 
The following section will focus on palmitoylation, its regulation and the role it plays 
in GPCR signalling events. 
 
1.3.1 Palmitoylation of GPCRs 
The palmitoylation of a GPCR was first demonstrated in bovine rhodopsin receptors in 
1984, and subsequently the palmitoylation site was determined (O'Brien and Zatz, 
1984, Ovchinnikov et al., 1988). Typical palmitoylation sites are cysteine residues in 
the C-terminal tail of the protein, located 10 to 14 amino acids downstream of the last 
transmembrane domain (Escriba et al., 2006). These cysteine residues have been found 
to be conserved in about 80% of all GPCRs (Escriba et al., 2006). Nonetheless, some 
studies suggested that alternative palmitoylation sites also exist, even for those 
receptors which are already palmitoylated at their C-tail (Escriba et al., 2006, Qanbar 
and Bouvier, 2003). For example, Mutation of all the cysteines in the C-terminus of the 
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μ opioid receptor failed to affect [3H] palmitic acid incorporation supporting the idea 
that palmitoylation site may not be limited to the C-terminus of the proteins (Chen et 
al., 1998). The study involving the substitution of C-terminal cysteines of the V1a 
vasopressin receptor also indicated an additional palmitoylation site at another locus in 
the receptor (Hawtin et al., 2001). 
For some plasma membrane proteins, studies have suggested that palmitoylation could 
serve a role in the processing and targeting of the protein to the correct membrane site. 
For example, palmitoylation-deficient CCR5 receptor resulted in both accumulation in 
intracellular stores and a profound decrease of membrane expression of the receptor 
(Percherancier et al., 2001). Lack of the palmitoylation site in bovine opsin expressed 
in COS cells led to the retention of the mutant receptors in the endoplasmic reticulum 
(Karnik et al., 1993). Similar results were also shown in the mutant luteinizing 
hormone/chorionic gonadotropin (LH/CG) receptor which has alanines instead of two 
cysteines in the C-terminus (Zhu et al., 1995). However, this is not the case for all 
GPCR proteins. The palmitoylation-deficient human β2-adrenergic receptor has similar 
receptor cell surface expression as the wild type (O'Dowd et al., 1989).  
In addition to receptor cell surface expression, palmitoylation is believed to have an 
impact on the GPCR signalling functions such as G protein coupling, internalisation 
and phosphorylation. The elimination of a palmitoylation site seems to exert a different 
influence on G protein coupling in terms of the type of receptor and G protein subtype. 
Loss of palmitoylation in LH/hCG receptor does not affect the efficiency of coupling 
to Gs protein (Kawate and Menon, 1994). Substitution of the palmitoylated cysteine by 
a glycine in β2-adrenergic receptor exhibited a drastically reduced ability to interact 
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with Gs protein, while no significant change in coupling to Gi protein was detected in 
palmitoylation-deficient α2A-adrenergic receptor (O'Dowd et al., 1989, Kennedy and 
Limbird, 1993). Palmitoylation of 5-Hydroxytryptamine receptor is critical for the 
coupling of the receptor with Gi protein and effector signalling (Papoucheva et al., 
2004). Moreover, CCR5 receptor palmitoylation sites were not required for 
Gi-mediated signalling but necessary for the efficient coupling to some other G protein 
subtypes (Blanpain et al., 2001). Human endothelin B contains three palmitoylation 
sites—cysteine 402, 403 and 405 (C402, 403 and 405). Without palmitoylation, the 
receptor failed to interact with either Gq or Gi, but with the first cysteine (C402) 
restored, the receptor was able to couple with Gq but not Gi (Okamoto et al., 1997). 
However, studies of human A1 adenosine receptor indicated that palmitoylation has 
little effect on receptor-G protein coupling, agonist-induce internalisation (Gao et al., 
1999).  
An investigation of the β2-adrenergic receptor also showed the palmitoylation mutant 
was highly phosphorylated and failed to undergo further phosphorylation when 
exposed to agonists, whereas the additional mutation of phosphorylation sites in the 
C-tail restored normal phosphorylation and receptor-Gs coupling, suggesting that the 
palmitoylation state regulates the β2-adrenergic receptor phosphorylation (Moffett et al., 
2001, Moffett et al., 1993, Moffett et al., 1996). The palmitoylation-deficient LH/hCG 
mutants have shown a higher ligand-induced internalisation rate than wild type, while 
the palmitoylation-defective Vasopressin V1a receptor exhibited decreased 
agonist-induced phosphorylation compared to wild type (Hawtin et al., 2001, Kawate 
and Menon, 1994, Munshi et al., 2005). Inhibition of CCR5 palmitoylation profoundly 
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reduced ligand-induced receptor phosphorylation, desensitisation and internalisation 
(Kraft et al., 2001, Oppermann, 2004). The non-palmitoylated 5-Hydroxytryptamine4a 
(5-HT4a) receptor mutant exhibited enhanced receptor phosphorylation under both 
basal and agonist stimulated conditions and more effective desensitisation and 
internalisation (Ponimaskin et al., 2005, Ponimaskin et al., 2002).  In vivo, the 
palmitoylation-less rhodopsin in transgenic knock in mice has been shown to become 
phosphorylated at a faster rate upon exposure to light resulting in a decreased 
sensitivity to light (Wang et al., 2005).   
 
1.3.2 Palmitoylation and PARs 
Palmitoylation appears to facilitate the expression of functional receptors on the cell 
surface and modulate receptor functions. In the PAR family, only PAR1 and PAR2 have 
potential typical palmitoylation sites on their C-tail, there is no cysteine residue in the 
C-terminus of either PAR3 or PAR4 (Figure 1.2, highlighted with green). The cysteine 
located at 361 of hPAR2 C-terminus was proved to be the palmitoylation site of hPAR2 
using autoradiography (Botham, 2007). The lack of the palmitoylation site caused 
decreased calcium signalling, but greater and prolonged ERK signalling towards 
agonists (Botham, 2007). The palmitoylation-deficient hPAR2 mutant also displayed a 
greater cell surface expression compared to wild type, and faster internalisation 
kinetics in response to the proteinase agonist, but not the peptide agonist (Botham, 
2007). But little work has been done on the palmitoylation state of PAR1. There are 
four cysteines located on the C-terminus of PAR1—C378, C387, C388 and C411 
(Figure 1.4). C387 and C388 are located 12 and 13 amino acids away from the last 
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transmembrane domain which are typical palmitoylation sites of GPCR. Using a 
computer model based on the 2.8 Å X-ray structure of rhodopsin, these two cysteines 
were predicted to be dual palmitoylation sites of PAR1 (Figure 1.4) (Swift et al., 2006). 
However, the role of these two cysteines in regulating PAR1 function is still unclear. 
 
 
 
 
 
 
 
Figure 1.4, hPAR1 structure showing the cysteines located at the C-terminus. 
There are four cysteins in the C-tail of hPAR1, respectively located 3, 12, 13 and 36 
amino acids away from the 7th transmembrane domain. 
 
 
1.4 Physiological role of PAR2, PAR3 and PAR4  
PARs are widely distributed in a number of different cell types in various systems. 
Studies using enzyme activators, PAR-AP and PAR-gene deficient mice provide strong 
evidence that PARs play a critical role in regulation of various physiological and 
pathophysiological functions in mammals including humans (Steinhoff et al., 2005). 
PARs are thus considered as a potential drug target.  
PAR1 has been detected in a variety of tissues, and will be described in detail in the next 
section. 
PAR2 has been found to be expressed in several human tissues including brain, heart, 
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kidney, stomach, pancreas, liver, small intestine and colon, and has been implicated in 
numerous different physiological and pathophysiological events (Cicala, 2002, 
Steinhoff et al., 2005). For example, PAR2 is highly expressed in vascular endothelial 
cells and smooth muscle cells. Activation of PAR2 by PAR2-AP causes the nitric oxide 
and prostaglandin mediated vasodilation in pre-contracted rat aorta, porcine coronary 
artery and in human in vivo, but no vascular contraction (al-Ani et al., 1995, Magazine 
et al., 1996, Robin et al., 2003, Hamilton and Cocks, 2000, Hamilton et al., 2001b, 
Hamilton et al., 2002). Studies have also revealed that PAR2 activation stimulated 
proliferation of cultured endothelial cells and smooth muscle cells (Mirza et al., 1996, 
Bretschneider et al., 1999, Koo et al., 2002). Moreover, the functional expression of 
PAR2 is increased in human arterial and venous conduits after exposure to inflammatory 
stimuli (Ritchie et al., 2007, Ballerio et al., 2007, Hamilton et al., 2001a). The injection 
of PAR2-AP in rat hind paw lead to significant oedema and granulocyte infiltration also 
suggesting the role of PAR2 in mediating inflammatory responses (Vergnolle et al., 
1999a).  
Human PAR3 is expressed in bone marrow, heart, brain, small intestine, airway smooth 
muscle, vascular endothelium and astrocytes etc (Ishihara et al., 1997, Hauck et al., 
1999, Bartha et al., 2000). However, no expression of the receptor on human platelets 
was observed, which differs from that observed with the murine receptor. In murine 
platelets, which express PAR3 and PAR4, PAR3 does not mediate thrombin signalling 
but instead functions as a cofactor to enhance PAR4 activation by thrombin 
(Nakanishi-Matsui et al., 2000). mPAR3 blocking antibodies and mPAR3-deficient mice 
have been shown to inhibit mouse platelet activation at low but not high thrombin 
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concentrations (Kahn et al., 1998, Ishihara et al., 1998), whereas mPAR4-deficient mice 
platelets completely failed to trigger platelet aggregation even at high thrombin 
concentrations (Sambrano et al., 2001). 
PAR4 has been identified and cloned from human, mouse and rat tissues. In human, 
Nothern blot analysis showed PAR4 mRNA in brain, testes, placenta, lung, liver, 
pancreas, thyroid, skeletal muscle, and small intestine (Xu et al., 1998, Striggow et al., 
2001, Steinhoff et al., 2005). Expression of PAR4 can also be found on human platelets, 
lung endothelial cells and vascular smooth muscle cells (Kahn et al., 1999, Fujiwara et 
al., 2005, Bretschneider et al., 2001). Although PAR1 is the predominant thrombin 
mediator in human platelets, activation of PAR4 on human platelets is sufficient to 
trigger calcium mobilization, platelet secretion and aggregation (Kahn et al., 1999). 
However, inhibition of PAR4 using a blocking antibody against the thrombin binding 
site of PAR4 had no effect in platelet activation (Kahn et al., 1999). PAR4 has been also 
reported as a receptor for cathepsin G as well as thrombin in human platelets (Sambrano 
et al., 2000). More recently it has been reported that PAR4 activation induced nitric 
oxide production in vascular endothelial cells (Momota et al., 2006) and contributed to 
vascular smooth muscle proliferation (Bretschneider et al., 2001). The involvement of 
PAR4 in inflammatory responses was also revealed through observations in vivo that 
thrombin and PAR4-AP, but not PAR1-AP induced leukocyte rolling and adherence in 
rat mesenteric venules (Vergnolle et al., 2002), and PAR4-deficient mice have no 
inflammatory responses after injection of soluble tissue factor into hind paw (Busso et 
al., 2008).  In vitro, the proinflammatory activity of thrombin is primarily mediated 
through the activation of PAR4 in human pulmonary artery endothelial cells (Bae and 
  33
Rezaie, 2008). The importance of PAR4 in inflammation was also highlighted in a study 
from our laboratory by Ramachandran showing that PAR4 expression can be induced in 
human lung fibroblasts following treatment with the inflammatory mediators TNF-α 
and LPS (Ramachandran et al., 2007). 
 
1.5 Physiological role of PAR1 
1.5.1 Cardiovascular system 
PARs are expressed by multiple cells in the cardiovascular and circulatory system 
including vascular endothelial cells and smooth muscle cells. Thrombin has been 
shown to be a major stimulator of platelets resulting in a series of subordinated events 
in platelet aggregation in vitro or in vivo (Eidt et al., 1988, Hung et al., 1992b, Kahn et 
al., 1999). Activation of PAR1 and PAR4 on human platelets is sufficient to trigger 
calcium mobilization, platelet secretion and aggregation (Kahn et al., 1999). 
Antibodies targeted against the thrombin interaction site of PAR1 results in the 
inhibition of human platelet activation at low thrombin concentrations but not high, 
while inhibition of PAR4 had no effect in platelet activation at either thrombin 
concentration (Brass et al., 1992, Kahn et al., 1999, Hung et al., 1992b). However, 
inhibition of both receptors markedly reduced platelet activation even when a high 
thrombin concentration was used (Kahn et al., 1999). The results suggest that PAR1 
appears to be responsible for mediating thrombin-induced responses in human platelets, 
and in the absence of PAR1 function, PAR4 can mediate platelet activation but only at 
high thrombin concentrations. PAR1 and PAR4 have been shown to have different 
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functions in regulating human platelets. The activation of PAR1 triggers the release of 
vascular endothelial growth factor and suppresses the release of endostatin from 
platelets, whereas PAR4 acts in a counter-regulatory manner (Ma et al., 2005). They 
have also been demonstrated to activate human platelets through distinct pathways 
(Voss et al., 2007, Holinstat et al., 2007, Bilodeau and Hamm, 2007). Moreover, PAR1 
appears to be more important than PAR4 in regulating platelet aggregation, blockade of 
PAR1 in monkeys attenuates thrombus formation even in the presence of PAR4 (Derian 
et al., 2003). 
PAR1 has been reported to regulate endothelial nitric oxide production via 
phosphorylation of endothelial nitric oxide synthase (Watts and Motley, 2009, Suzuki et 
al., 2009). Activation of endothelial PAR1 causes endothelium–dependent vasodilation, 
which is mediated by the release of endothelial nitric oxide. Thrombin and PAR1-AP 
result in a relaxation of pre-contracted blood vessels isolated from a number of species 
such as the human pulmonary artery (Hamilton et al., 2001b), porcine coronary artery 
(Hamilton and Cocks, 2000) as well as in a few smaller vessels such as the human and 
porcine intramyocardial arteries (Hamilton et al., 2002). Furthermore, PAR1 appears to 
modulate both vasodilator and contractile responses in rat aorta (Magazine et al., 1996). 
Moreover, PAR1–AP caused the relaxation of smooth muscle cells in both human 
internal mammary artery and saphenous vein (Ballerio et al., 2007), and in vivo a study 
in rats has revealed that PAR1 mainly mediates hypertension (Cicala et al., 2001). 
Activation of PAR1 can cause proliferation of cultured rat vascular smooth muscle cells 
(Chaikof et al., 1995, McNamara et al., 1993). PAR1 has been implicated in mediating 
vascular inflammatory responses. Activation of PAR1 through intraplantar injection of 
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PAR1-AP in rat paw caused oedema which was partly due to PAR1 mediated plasma 
extravasation to tissue (Vergnolle et al., 1999b). Studies have shown that PAR1 
mediates protective effects of activated protein C in enhancing the integrity of the 
vascular barrier during inflammation in vivo and in vitro (Schuepbach et al., 2009, 
Schuepbach et al., 2008). 
 
1.5.2 Respiratory system 
PAR1 is detectable on numerous airway associated cell lines including pulmonary 
fibroblasts (Trejo et al., 1996, Chambers et al., 1998) and epithelial cells (Asokananthan 
et al., 2002), endothelial cells (D'Andrea et al., 1998, Kataoka et al., 2003) as well as 
smooth muscle cells (Lan et al., 2000, Walker et al., 2005). 
An important function of PAR1 activation in the lung is the mediation of cell 
mitogenesis (Blanc-Brude et al., 2005, Walker et al., 2005), although some studies 
indicated that thrombin but not PAR1-AP mediated mitogenesis, and suggested a 
PAR-independent mechanism in the mitogenic action of thrombin (Tran and Stewart, 
2003, Walker et al., 2005). Thrombin is also shown to stimulate procollagen 
production in lung fibroblasts and upregulate connective tissue growth factor 
production during tissue repair via PAR1 activation (Chambers et al., 1998, Chambers 
et al., 2000). Work further supporting the importance of PAR1 in the pulmonary 
fibrotic response has been carried out in rats using bleomycin-induced pulmonary 
fibrosis (Howell et al., 2001; Howell et al., 2002). PAR1 expression is significantly 
increased in a bleomycin induced model of pulmonary fibrosis, and use of a thrombin 
inhibitor significantly reduced connective tissue growth factor mRNA level and 
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collagen accumulation (Howell et al., 2001, Howell et al., 2002). PAR1 mediated 
thrombin signalling has been revealed to stimulate IL-6, IL-8, and PGE2 release from 
human lung epithelium cells, and as well as the expression of platelet-derived growth 
factor (Asokananthan et al., 2002). PAR1 is also involved in regulating airway tone. 
Thrombin acting via PAR1 caused the contraction of human bronchial rings in vitro and 
contraction of guinea-pigs in vivo (Hauck et al., 1999, Cicala et al., 1999). However, in 
mouse isolated trachea, PAR1 has been revealed to mediate the relaxation of tracheal 
smooth muscle through prostaglandin PGE2 release (Lan et al., 2001). Activation of 
PAR1 by Pen c 13, a mold allergen, induced IL-8 production in human airway 
epithelail cells, suggesting an important role in the pathogenesis of this form of asthma 
(Chiu et al., 2007). 
 
1.5.3 Gastrointestinal system 
Involvement of PAR1 in the gastrointestinal system is mainly in ion transport, 
permeability, motility and inflammation, however, the opposite effects are sometimes 
observed in different cell type (Vergnolle, 2005, Vergnolle, 2008). 
PAR1 has been found on endothelial cells (Vergnolle et al., 2004), epithelial cells 
(Buresi et al., 2001, Buresi et al., 2002), smooth muscle cells (Kawabata et al., 2004b), 
myofibroblasts (Seymour et al., 2003) and on enteric neurons (Corvera et al., 1997). 
Activation of PAR1 stimulates chloride secretion from intestinal epithelial cells in a 
calcium- and MAP kinase-dependent pathway, thus enhancing the fluid secretion, 
resulting in diarrhea as well as serving a protective function by flushing away potential 
pathogens and toxins during intestinal inflammation (Buresi et al., 2001, Buresi et al., 
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2002, Vergnolle, 2008). Further, researchers have shown that PAR1 was overexpressed 
in the colon of inflammatory bowel disease (IBD) patients, and in a mouse model of 
IBD, administration of PAR1-AP into the colon of mice provoked an inflammatory 
reaction, while PAR1 antagonists significantly decreased the mortality and severity of 
colonic inflammation (Vergnolle et al., 2004). 
PAR1 activation is also reported to increase intestinal barrier permeability, and thus 
regulates the passage of fluids and microorganisms across the gut mucosa (Chin et al., 
2003). Activation of PAR1 in guinea pigs stimulates contraction of the gastric 
longitudinal smooth muscles (Saifeddine et al., 2001), but causes relaxation of mouse 
gastric and colonic muscles (Cocks et al., 1999, Mule et al., 2002). Further to this, in 
vivo studies have demonstrated that activation of PAR1 can enhance gastrointestinal 
transit in mice (Kawabata et al., 2001). Recently, Lee et al. reported that PAR1 
activation causes contraction in the human and guinea-pig gallbladders and may play 
important roles in the control of gallbladder motility (Lee and Huang, 2008).  
 
1.5.4 Nervous system 
PAR1 has been shown to be expressed throughout the nervous system such as 
hippocampus, cortex and amygdale (Striggow et al., 2001). PAR1 expression has 
further been revealed in human astrocytoma cells (Grishina et al., 2005) and in guinea 
pig myenteric (Corvera et al., 1999) and submucosal neurons (Reed et al., 2003). 
The morphology and proliferation of astrocytes has been shown to be affected by both 
thrombin and PAR1-AP. PAR1 activation has been demonstrated by several groups to 
stimulate astrocytes to transform from their normally stellate shape into a polygonal 
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morphology (Nicole et al., 2005). It has been reported that PAR1 activation induced 
proliferation of the resting astrocytes after brain injury and is involved in astrogliosis, 
an astrocyte proliferation-dependent disorder in vivo (Nicole et al., 2005). The 
activation of PAR1 by thrombin in neuronal cells has also been shown to protect 
neuronal cells and astrocytes from cell death induced by hypoglycaemia and oxidative 
stress (Vaughan et al., 1995). Thrombin and PAR1-AP have also been revealed to affect 
the morphology of tyrosine hydroxylase-positive neurons resulting in increased neurite 
elongation and delayed branching (Debeir et al., 1998). In vitro studies on cultured 
neurons and astrocytes indicated that thrombin and PAR1-AP can attenuate astrocyte 
stellation and neurotoxicity induced by β-amyloid which is a putative causative agent in 
Alzheimer’s disease, whilst increase β-amyloid induced expression of basic fibroblast 
growth factor (Pike et al., 1996). In rat primary astrocytes, the activation of PAR1 
mediates thrombin-induced upregulation of matrix metalloprotease-9 which is a 
zinc-dependent enzyme involved in the breakdown of extracellular matrix during 
normal physiological processes (Choi et al., 2008). Recently, PAR1 has been implicated 
in HIV associated neurodegenerative disorders. Brain sections taken from patient with 
HIV encephalitis showed increased level of PAR1 in astrocytes (Boven et al., 2003). 
PAR1 is also upregulated in Parkinson disease affected brain tissue (Ishida et al., 2006), 
and further provides a thrombin mediated protective pre-conditioning against Parkinson 
disease related behavioural deficits (Cannon et al., 2006). Moreover, PAR1 has been 
found in rat olfactory neurons and the addition of thrombin and PAR1-AP resulted in a 
rapid neurite retraction suggesting a role of PAR1 in neuritogenesis (Olianas et al., 
2007). 
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1.5.5 Renal system 
Abundant expression of PAR1 mRNA in the kidney was initially reported by 
Rasmussen et al (Rasmussen et al., 1991). Since then PAR1 has been shown to be 
present in endothelial, mesangial and epithelial cells in normal human kidney tissue 
(Grandaliano et al., 2000) as well as in primary human renal carcinoma cells 
(Kaufmann et al., 2002). It was observed that in fibrin associated renal diseases such as 
thrombotic microangiopathy and extracapillary glomerulonephritis, PAR1 protein 
expression reduced with an increase mRNA level within the glomerular lesion (Xu et 
al., 1995). Another study in vivo in a murine model of crescentic glomerulonerphritis 
revealed that PAR1 activation enhanced glomerular crescent formation, T cell and 
macrophage infiltration, fibrin deposition and elevated serum creatinine, which are 
prominent features of glomerulonephritis (Cunningham et al., 2000), suggesting a 
important role for PAR1 in the pathogenesis of crescentic glomerulonephritis. In 
addition, PAR1 activation resulted in renal vasodilation and a marked reduction in the 
glomerular filtration rate in isolated perfused rat kidney, suggesting the involvement of 
PAR1 in the regulation of renal haemodynamics (Gui et al., 2003). 
 
 
 
 
 
 
 
  40
1.6 Working hypothesis 
The hypothesis of this study is that “The hPAR1 C-terminal cysteines regulate 
receptor function.” 
 
1.7 Aims 
In order to test this hypothesis the specific aims of this study were to determine: 
 the effect of C387, C388 in regulating receptor functions such as receptor cell 
surface expression, downstream signalling and receptor internalisation 
 whether C387, C388 is palmitoylated  
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2 General materials and methods 
2.1 Introduction 
hPAR1 has three cysteines located at 387, 388 and 411 in the C-tail as shown in Figure 
2.1, C387 and C388 are considered as putative palmitoylation sites of hPAR1. In this 
chapter, hPAR1 was ligated into plasmid vectors and KNRK cells were transfected with 
this construct, generating a stably expressing wild type cell line. In order to investigate 
the roles of these cysteine residues, C387, C388 and C411 were each replaced by 
site-directed mutagenesis with an alanine to generate single mutants; C387 and C388 
were also substituted by alanines simultaneously to create a double mutant. Alanine 
has a similar chemical structure with cysteines and thus was chosen to replace 
cysteines in hPAR1 for avoiding the whole protein structure alteration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1, Representative model of hPAR1 used in this study. Wild type hPAR1 
(POMC-M1-hPAR1-HA11) possessed an N-terminal pro-opiomelanocortin (POMC) 
singal peptide followed by an M1 epitope, a HA11 epitope was fused to the C-terminal 
tail. (See Appendix for DNA sequence and protein sequence) 
 
The aim of the chapter was to generate the cell lines perminantly expressing wild type 
hPAR1, hPAR1C387A, hPAR1C388A, hPAR1C387AC388A and hPAR1C411A to use in 
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the later chapters. 
 
2.2 Materials and reagents 
Primers were purchased from MWG Biotechnology, Ebersberg, Germany. Restriction 
endonucleases HindIII and XhoI were purchased from New England Biolabs, Hitchin, 
Hertfordshire, UK. Quick change site-directed mutagenesis kit and XL-1 blue 
supercompetent E.coli were obtained from Stratagene, Amsterdam, The Netherlands. 
QIAprep miniprep kit was obtained from Qiagen, Crawley, West Sussex, UK. 
LipofectAMINE, Opti-Mem, Fluo-3 acetoxymethyl ester (Fluo-3 AM), Phosphate 
Buffer Saline (PBS), geneticin (G418-sulphate), Dulbecco’s Modified Eagle Medium 
(DMEM), sodium pyruvate, penicillin/streptomycin/L-glutamine (PSG), and Foetal 
Calf Serum (FCS) were supplied by Invitrogen, Paisley, UK. Anti-PAR1 ATAP-2 
mouse monoclonal antibody was purchased from Zymed Laboratories Inc, San 
Francisco, USA. Human plasma thrombin was obtained from Calbiochem, UK. Human 
PAR1-AP TFLLR-NH2 was obtained from peptide international, Kentucky, USA. All 
other chemicals and reagents were purchased from Sigma-Aldrich, Poole, Dorset, UK.  
Kirsten virus sarcoma transformed rat kidney epithelial cells (KNRK) were purchased 
from American Tissue Type Culture Collection (Bethesda, MD, U.S.A). The vector 
pcDNA 3.1 containing wild type hPAR1 (wt-hPAR1, Figure 2.1) and wt-hPAR1-KNRK 
cell line were supplied by supervisor Dr. S.J. Compton. 
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2.3 Methods 
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2.3.1 Construction of C-terminal cysteine deleted hPAR1 cDNAs 
(C387A, C388A, C387AC388A, C411A)  
2.3.1.1 Site-directed mutagenesis 
The specific oligonucleotide primers for the different hPAR1 mutants were designed 
between 25-45 base pairs long using primer X (http://bioinformatics.org/primerx) with 
a melting temperature (Tm) 75-85˚C, a GC content of approximately 40-60%, and a G 
or C terminator. The sequences of the primers in which the corresponding cysteine was 
replaced by an alanine are displayed below (the mutations have been highlighted).  
 
C387A primers 
5’-CGT CTA CAG TAT CTT AGC CTG CAA AGA AAG TTC CG-3’ 
3’-GCA GAT GTC ATA GAA TCG GAC GTT TCT TTC AAG GC-5’ 
 
C388A primers 
5’-CGT CTA CAG TAT CTT ATG CGC CAA AGA AAG TTC CGA TCC-3’ 
3’-GCA GAT GTC ATA GAA TAC GCG GTT TCT TTC AAG GCT AGG-5’ 
 
C387AC388A primers 
5’-GGT ACG TCT ACA GTA TCT TAG CCG CCA AAG AAA GTT CCG ATC CC-3’ 
3’-CCA TGC AGA TGT CAT AGA ATC GGC GGT TTC TTT CAA GGC TAG GG-5’ 
 
C411A primers 
5’-GCA AGT AAA ATG GAT ACC GCC TCT AGT AAC CTG AAT AAC-3’ 
3’-CGT TCA TTT TAC CTA TGG CGG AGA TCA TTG GAC TTA TTG-5’ 
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For each hPAR1 mutant, the mutagenesis reaction was prepared in a total volume of 50 
μl as follows: 
10×reaction buffer               10% (v/v) 
Plasmid DNA template          1 ng/μl 
Forward primer                  2.5 ng/μl      
Reverse primer                  2.5 ng/μl 
dNTP mix                      0.5 mM 
DNA polymerase (2.5 U/μl)         0.5 U/μl 
DEPC H2O was added to reach a final volume. Afterwards, the mutagenic PCR was 
placed in a thermal cycler to run the following cycles: 
Cycles Temperature Time 
1 95˚C 30 sec 
16 95˚C 30 sec 
55˚C 1 min 
68˚C 14 min 
 4˚C Forever 
Table 2.3.1, Conditions of Mutagenic PCR 
Following the PCR reaction, the PCR product was incubated for 1 hour at 37˚C with 
DpnI restriction enzyme (10 U/μl) to digest the parental vector. Finally, gel 
electrophoresis was performed to check the presence of the PCR products. 
 
2.3.1.2 Bacterial transformation 
1.7 μl of 10% β-mercaptoethanol (β-ME) was added to 50 μl of XL1-Blue 
supercompetent E.coli. The cells were incubated on ice for 10 min with gentle agitation 
every 2 min. Then 7 μl of mutant DNA from the PCR reaction was added into the 
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β-ME treated E.coli swirled and incubated on ice for a further 30 min. The E.coli were 
heat shocked at 42˚C in a water bath for 45 sec and then immediately returned to ice 
for a further 2 min. 500 μl of preheated (42˚C) LB Broth was added to the E.coli before 
placing the suspension in a 37˚C, 200 rpm shaking incubator for one hour. Following 
incubation, 250 μl of the E.coli was plated onto an LB agar plate containing 100 μg/ml 
ampicillin and incubated at 37˚C overnight. 
 
2.3.1.3 Screening colonies and harvesting mutant DNAs 
Individual colonies (upto 6 for each mutant) from the transformed E.coli plate were 
randomly picked, and placed into 30 ml universal tubes containing 5 ml of LB broth 
with 100 μg/ml ampicillin. The universal containers were then incubated at 37˚C at 
200 rpm overnight to allow the colonies to grow. 
The QIAprep Miniprep Kit was utilized to extract and purify the plasmid DNA from 
the overnight cultures. 5 μl of the purified DNA was digested by HindIII and XhoI 
restriction enzymes in NEBuffer 2 at 37˚C for 1 hour, and then run on a 1.3% agarose 
gel to assess the presence of the insert fragment. The concentration of purified DNA 
was assessed using a GeneQuant RNA/DNA Calculator (Biochrom LTD, Cambridge, 
UK) and an aliquot of the sample DNA was sent to MWG (MWG Biotech, London, 
UK) for sequencing. The construct containing the correct insert sequence was selected 
for each mutant. 
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2.3.2 Generation of mutant hPAR1 permanently expressing cell lines 
2.3.2.1 Tranfection 
KNRK cells were transfected with the mutant hPAR1 DNAs using the lipofectAMINE 
method. The KNRK cells were plated onto a 65 mm diameter petri dish in normal 
growth medium and allowed to reach 60-80% confluence by the day of transfection. 
Two Falcon 5 ml polystyrene round bottom tubes each containing 1 ml of Opti-Mem 
were prepared. To one tube which was labelled “1”, 5 μg of the mutant DNA was 
added and 20 μl LipofectAMINE was added to the other tube labelled “2”. The two 
tubes were vortexed for upto 4 sec and incubated at room temperature (RT) for 15 min. 
Meanwhile, the medium was removed from the cells and replaced with 4 ml of 
Opti-Mem. Before incubating at RT for a further 15 min, the contents of tube 2 were 
poured directly into tube 1 and vortexed again for upto 4 sec. The Opti-Mem was 
removed from the KNRK cells, and then the DNA/LipofectAMINE/Opti-Mem mixture 
was added to the cells. The cells were then incubated at 37˚C, 5% CO2 for 24 h before 
replacing the medium with fresh normal growth medium. After incubating for a further 
24 h, the cells were harvested and transferred to a 25 cm2 flask with selective growth 
medium. A mock transfected KNRK cell line was produced by transfecting KNRK 
cells with pcDNA 3.1 vectors only using the method described above (empty 
vector-KNRK, EV-KNRK). 
 
2.3.2.2 Cell culture 
KNRK cells were propagated in normal growth medium (DMEM, 10% FCS, 100 U/ml 
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penicillin, 100 μg/ml streptomycin, 292 μg/ml glutamine and 100 μM sodium 
pyruvate). The transfected KNRK cell lines stably expressing either wt-hPAR1 or 
mutant hPAR1 were grown in selective growth medium (DMEM, 10% FCS, 100 U/ml 
penicillin, 100 μg/ml streptomycin, 292 μg/ml glutamine, 100 μM sodium pyruvate 
and 0.7 mg/ml G418). All cell lines were maintained at 37˚C in a humidified 
atmosphere containing 5% CO2. Cells were routinely passaged using 0.5 mM 
ethylenediamine tetraacetic acid (EDTA). 
 
2.3.2.3 Single cell cloning and clone selection 
Once transfected KNRK cells reached 60-80% confluent in the 75 cm2 flask, they were 
harvested, and counted using a haemocytometer before diluting to 5 cells/ml in 
selective growth medium. This diluted suspension was then transferred to a 96 well 
plate (200 μl per well). The 96 well plate was incubated at 37˚C, 5% CO2 until 
colonies of cells became visible in the wells (approximately two weeks). The cells 
within the wells clearly containing only one colony were transferred to 25 cm2 flasks 
with 5 ml of selective growth medium. At least 40 colonies were picked up for the 
single mutant cell line screening and ~80 colonies were selected for that of the double 
mutant. 
When the cells reached 60-80% confluence in the 25 cm2 flasks, fluorescence activated 
cell sorting (FACS, see section 2.3.2.4) was performed against EV-KNRK to identify 
the expressing mutant hPAR1 colonies. The clone showing the highest level of receptor 
cell surface expression above control in FACS analysis was selected, and taken 
through a second round of single cell cloning to ensure that the final cell line was 
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derived from a single cell. The colonies from the second round were analysed by 
FACS and calcium signalling assay (see section 2.3.2.5). The procedure therefore for 
obtaining a single cell line took upto 3 months. 
 
2.3.2.4 Fluorescence activated cell sorting 
Cells were harvested, transferred to a 5 ml falcon tube, and centrifuged at 3000 g at 
4˚C for 5 min. The supernatant was discarded and the cell pellet was resuspended in 
200 μl of ice-cold PBS, 1/300 dilution of mouse anti-PAR1 antibody (ATAP-2) was 
added to the cell suspension. The sample was then incubated on ice for one hour, 
gently swirling every 15 min. 1 ml of cold PBS was then added to the sample before 
centrifuging at 3000 g at 4˚C for 5 min. The supernatant was discarded and the cell 
pellet was resuspended again in 200 μl of cold PBS. 1/100 dilution of anti-mouse IgG 
(FITC conjugate) antibody was added and incubated for 45 min on ice with swirling at 
15 min intervals. 1 ml of cold PBS was then added to the cell suspension and 
centrifuged at 3000 g at 4˚C for 5 min. The supernatant was then disposed of and the 
cell pellet was resuspended in 300 μl of cold PBS. This washing step was repeated one 
more time, and the cells were suspended in 300 μl of cold PBS. 5 μg/ml of propidium 
iodide was added to the sample before analysing in a Beckton Dickinson flow 
cytometer.  
 
2.3.2.5 Calcium signalling assay 
Cells were harvested, transferred to a 30 ml universal tube and then centrifuged at 
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3000 g for 5 min. The supernatant was discarded and the cell pellet was resuspended in 
1ml of normal growth media containing 22 μM Fluo-3 AM (in dimethylformamide) 
and 250 μM sulphinpyrazone. The cell suspension was then placed on an orbital shaker 
at 100 rpm at RT for 30 min. After incubation, the cells were washed with 4 ml of PBS 
by centrifugation. The supernatant was then discarded and the treated cell pellet was 
resuspended in 1.5 ml of Calcium assay buffer (CAB, 20 mM HEPES, 150 mM NaCl, 
3 mM KCl, 10 mM glucose, 250 μM sulphinpyrazone and 1.5 mM CaCl2·6H2O, and 
then adjusted to pH 7.4.) The cell suspension was then aliquoted in 100 μl amounts 
into 15 cuvettes. Each cuvette contained a magnetic flea and 1880 μl of CAB. The 
samples were placed in a fluorospectrometer (Photon Technology International, West 
Sussex, UK) which was set to emit an excitation wavelength of 480 nm and record 
emissions at a wavelength of 530 nm. Each cuvette was recorded for about 2 min in 
order to get a stable baseline. Agonists, either 10 U/ml thrombin or 50 μM TFLLR 
were added, and the maximum fluorescence response stimulated by the agonists were 
read and recorded. Calcium ionophore (2 μM) was used to obtain the maximal 
fluorescence response.  
 
2.3.2.6 Generation of low wt-hPAR1 
To generate low expressing wild-type hPAR1 (low wt-hPAR1), the receptor expression 
was found to decrease with the rise of cell confluence and reach the optimal expression 
level after about 48 h of splitting. Therefore, all the experiments were carried out using 
the cells in the second day after passaging. 
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2.4 Statistical analysis 
Results are expressed as mean ± S.E. Comparison of data among groups were 
performed with one-way ANOVA followed by a Dunnett’s multiple comparison test or 
a Bonferroni’s Multiple Comparison test. A paired t test was used for measuring the 
differences between two groups. An associated probability (P value) of <0.05 was 
considered significant. 
 
2.5 Results 
Four mutant hPAR1 stably expressing cell lines were successfully generated by single 
cell cloning and screened by both FACS and calcium signalling assay. Representative 
FACS traces are shown in Figure 2.5.1. The solid purple indicates the EV-KNRK and 
mutant cell lines are represented as green lines (Fig 2.5.1). The mutant cell lines all 
have a clear rightward shift in fluorescence level against EV-KNRK (Fig 2.5.1). Figure 
2.5.2 displays representative hPAR1 mediated calcium signalling in response to 
thrombin and the internal control calcium ionophore. hPAR1C387A, hPAR1C388A and 
hPAR1C411A show an increase in the fluorescence level after the addition of 10 U/ml 
thrombin (Fig 2.5.2a, b, d). hPAR1C387AC388A, EV-KNRK failed to trigger an 
increase in calcium levels in response to thrombin (Fig 2.5.2c, e). All the cell lines 
displayed a rapid increase in the fluorescence level in response to 2 µM calcium 
ionophore (Fig 2.5.2). The cell lines were checked by FACS regularly to assess the 
stable receptor expression. 
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Figure 2.5.1, FACS analysis of the receptor cell surface expression. EV-KNRK is 
shown as solid purple and mutant cell lines are shown as green lines.          
(a) hPAR1C387A,  (b) hPAR1C388A, (c) hPAR1C387AC388A, (d) hPAR1C411A 
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Figure 2.5.2, calcium imaging. Intracellular calcium signalling in the (a) 
hPAR1C387A (b) hPAR1C388A (c) hPAR1C387AC388A (d) hPAR1C411A (e) 
EV-KNRK cell line following activation by an agonist and addition of calcium 
ionophore 
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2.6 Discussion 
hPAR1 has 3 cysteines in the C-tail—C387, C388 and C411. Using site-directed 
mutagenesis C387A, C388A, C387AC388A and C411A mutants were successfully 
generated. Cell lines stabely expressing the mutant receptors were successfully 
generated and the cell surface expression was observed by FACS. All the hPAR1 
mutants responded to thrombin except hPAR1C387AC388A. Moreover, mock 
transfected KNRK cells failed to respond to thrombin as expected. 
These four cell lines stably showing hPAR1 were utilized for future analysis and 
passaged up into larger flasks before being stored in liquid nitrogen in FCS with 10% 
dimethyl sulfoxide (DMSO). 
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3 The role of C-terminal cysteines in calcium 
signalling 
3.1 Introduction 
IP3/DAG pathway is an important GPCR-triggered downstream event which results in 
an elevation of cytosolic calcium ions (Ca2+). The activation of GPCRs subsequently 
activates the effector Gq or Go proteins which in turn activates phospholipase C (PLC). 
The membrane bound lipid phosphatidylinositol 4,5-bisphosphate (PIP2) is then 
cleaved by activated PLC into two second messengers: inositol 1,4,5-trisphosphate (IP3) 
which can freely diffuse into the cytosol, and 1,2-Diacylglycerol (DAG), a lipophilic 
molecule that remains associated with the cell membrane. Diffused IP3 binds to Ca2+ 
channel in the endoplasmic reticulum (ER) membrane and induces an opening of the 
channel, causing the release of stored Ca2+ from the ER into the cytosol and thus a rise 
of the cytosolic Ca2+ concentration. However, the IP3-mediated cytosolic Ca2+ rise is 
transient since after it’s generation IP3 is rapidly hydrolyzed to inositol 1,4- 
bisphosphate, which can not bind to the Ca2+ channel and thus does not stimulate Ca2+ 
release from the ER. Furthermore, Ca2+ pumps in the plasma membrane and ER 
membrane would transport Ca2+ from the cytosol to the cell exterior and back into the 
ER lumen respectively. PAR1 as a GPCR has been shown to couple with Gq protein 
leading to the activation of PLC and calcium mobilization (Figure 3.1). Upon 
activation by thrombin and PAR1-AP, PAR1 is shown to signal through Ca2+ (Vu et al., 
1991a). 
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Figure 3.1, IP3/DAG pathway. Intracellular calcium mobilisation mediated by PAR1 
triggered IP3/DAG pathway. 
 
Aims 
The aim of the study in this chapter was to investigate the effect of hPAR1 putative 
plamitoylation sites—C387 and C388 in the receptor cell surface expression and 
calcium signalling. 
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3.2 Materials and Methods 
3.2.1 Reagents and materials 
All the reagents and the chemicals used in this chapter are described in section 2.1. 
 
3.2.2 Methods 
The cell surface expression levels of wt-hPAR1, hPAR1C387A, hPAR1C388A and 
hPAR1C387AC388A were analysed against EV-KNRK by FACS as described in 
section 2.3.2.4. 
Calcium signalling assays for wt-hPAR1, low wt-hPAR1 and hPAR1 mutant cell lines 
were performed as detailed in section 2.3.2.5. Agonists, either thrombin (0.03-10 U/ml) 
or TFLLR (0.316-100 μM) were added, and the maximum fluorescence response 
stimulated by the agonists were read and recorded. The responses for each cell sample 
were calculated by subtracting the base fluorescence from the peak fluorescence. The 
average response for each agonist concentration was expressed as a percentage of the 
mean response of calcium ionophore (maximum attainable response). 
 
3.3 Results 
3.3.1 C-terminal cysteines affect hPAR1 cell surface expression 
FACS analysis of wt-hPAR1 and mutant hPAR1 cell surface expression was carried out 
in order to characterise the effect of C-terminal cysteines on the receptor expression. 
The data obtained shows that hPAR1C387A and hPAR1C388A cell lines have similar 
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cell surface expression to that of wt-hPAR1 (80%) (Fig 3.3.1). The statistical analysis 
shows that there was no significant different in expression level between wt-hPAR1 and 
the two single mutants (P>0.05). However, there was a dramatic decrease in the 
hPAR1C387AC388A cell surface expression compared to wt-hPAR1 cell line (P<0.01); 
its expression level was found to be approximately 40% of that of wt-hPAR1 (Fig 
3.3.1). 
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Figure 3.3.1, Comparative FACS analysis of wt-hPAR1 and mutant hPAR1 
expressing cell lines. EV was used as a negative control. Histograms shown present 
the means ± S.E. from four experiments performed in duplicate (P<0.001, n=5).  
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3.3.2 C-teminal cysteines regulate hPAR1 calcium signalling 
With the purpose of investigating the effect of deleted cysteines on receptor signalling, 
agonist triggered calcium signalling assays were performed. The cell lines were treated 
with different concentrations of PAR1 agonists (either TFLLR or thrombin). The 
concentration effect curves are shown in Figure 3.3.2 and their EC50 values are listed in 
Table 3.1. The wt-hPAR1, hPAR1C387A, hPAR1C388A and hPAR1C411A triggered 
calcium responses were concentration dependent in response to thrombin and TFLLR. 
The thrombin effect curves for wt-hPAR1, hPAR1C387A, hPAR1C388A and 
hPAR1C411A all plateau at ~45% of maximum obtainable signal (% of A23187). The 
TFLLR curves for wt-hPAR1, hPAR1C387A, hPAR1C388A and hPAR1C411A all reach 
~50% of maximum obtainable signal at 100 µM TFLLR dose. There were no 
significant differences among the concentration effect curves for hPAR1C387A, 
hPAR1C388A and hPAR1C411A compared to wt-hPAR1 in response to either TFLLR 
or thrombin (P>0.05). However, hPAR1C387AC388A and EV-KNRK failed to respond 
to both hPAR1 agonists (Fig 3.3.2).   
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Figure 3.3.2, hPAR1 agonists triggered calcium signalling. (a) Thrombin 
concentration effect curve for wt-hPAR1, hPAR1C387A, hPAR1C388A, hPAR1C387A 
C388A, hPAR1C411A and EV. (b) TFLLR-NH2 concentration effect curve for 
wt-hPAR1, hPAR1C387A, hPAR1C388A, hPAR1C387A C388A, hPAR1C411A and EV. 
The results present the means ± S.E. from at least three experiments performed in 
duplicate. 
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Cell lines EC50 Thrombin (U/ml) 
EC50 
TFLLR (µM) 
WT 0.173 ± 1.411 14.1 ± 1.175 
C387A 0.367 ± 1.283 20.5 ± 1.512 
C388A 0.183 ± 1.495 4.91 ± 1.365 
C411A 0.194 ± 1.417 9.24 ± 1.447 
 
Table 3.1 Mean EC50 values ± S.E. of thrombin and TFLLR concentration effect 
curves for wt-hPAR1, hPAR1C387A, hPAR1C388A and hPAR1C387AC388A 
 
3.3.3 Comparison of low wt-hPAR1 and hPAR1C387AC388A 
The expression of low wt-hPAR1 was matched to that of hPAR1C387AC388A (Fig 
3.3.3). When analysed using one-way ANOVA and Bonferroni’s Multiple Comparison 
test, low wt-hPAR1 displayed comparable cell surface expression as 
hPAR1C387AC388A (P>0.05), but highly significantly different expression level with 
wt-hPAR1 (P<0.001). The agonist (either TFLLR or thrombin) concentration effect 
curves for low wt-hPAR1 are shown in Figure 3.3.4. From this data it appears that the 
response of low wt-hPAR1 is agonist concentration dependent. In response to thrombin 
low wt-hPAR1 triggered a calcium signal as low at 0.3 U/ml and reached maximal 
response at 10 U/ml (Fig 3.3.4a), and in response to TFLLR low wt-hPAR1 triggered a 
calcium signal as low at 3.16 μM and reached maximal response at 100 μM (Fig 
3.3.4b). However, hPAR1C387AC388A failed to respond to the maximal dose of either 
agonist (Fig 3.3.4). 
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Figure 3.3.3, FACS analysis of cell surface expression of hPAR1C387AC388A, 
wt-hPAR1 and low expression wt-hPAR1. EV was used as the negative control. The 
results represent the means ± S.E. from four experiments performed in duplicate 
(P<0.0001, n=4).  
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Figure 3.3.4, hPAR1 agonists triggered calcium signalling in hPAR1C387AC388A 
and low wt-hPAR1. (a) thrombin concentration effect cure for the low wt-hPAR1 and 
hPAR1C387AC388A cell lines. (b) TFLLR concentration effect curve for the low 
wt-hPAR1 and hPAR1C387AC388A cell lines. The results represent the means ± S.E. 
from 3-5 experiments performed in duplicate.  
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3.4 Discussion  
The main finding in this chapter was that the putative palmitoylation sites—Cysteine 
387 and 388 within hPAR1 C-tail play an important role in the receptor cell surface 
expression. Compared to wt-hPAR1, both hPAR1C387A and hPAR1C388A displayed 
approximately 80% cell surface expression, and hPAR1C387AC388A only displayed 
approximately 40% cell suface expression. Additionally, these two cystienes are 
critical for receptor coupling to calcium. hPAR1C387A and hPAR1C388A have similar 
sensitivity towards PAR1 agonists (thrombin and TFLLR) as wt-hPAR1, but 
hPAR1C387AC388A failed to respond to either agonist.  
The double substitution of the two cysteines (C387 and C388) in hPAR1 resulted in a 
60% decrease in the receptor cell surface expression. Replacement of either cysteines 
resulted in receptor expression similar (80%) to the wild type. The results strongly 
suggest that the putative palmitoylation site is important in hPAR1 cell surface 
expression, but one cysteine is adequate to return the receptor expression level. Our 
data is consistent with the study of the palmitoylation sites in vasopressin V2 receptor 
(Sadeghi et al., 1998, Schulein et al., 1996). Elimination of the palmitoylation sites 
(Cys341 and Cys342) in vasopressin V2 receptor lead to a 30% reduction of cell 
surface expression, however, palmitoylation of either one of the two cysteines was 
sufficient to restore cell surface expression to wild type level (Sadeghi et al., 1998, 
Schulein et al., 1996). Moreover, in the CCR5 receptor, single and double cysteine 
mutant receptors exhibited altered cell surface expression but the 
palmitoylation-deficient mutant displayed a more dramatic reduction in cell surface 
expression (Percherancier et al., 2001, Blanpain et al., 2001). Loss of mutant receptor 
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cell surface expression may be caused by decreased protein synthesis or export 
impairment. Prevention of palmitoylation resulted in mutant LH/CG receptors  
trapped intracellularly (Zhu et al., 1995), and the CCR5 mutant without 3 
palmitoylated cysteines was sequestered in intracellular biosynthetic compartments 
although it was synthesised efficiently (Blanpain et al., 2001). The hPAR1 location 
could be identified by either confocal microscopy or immunofluorescence microcopy 
to see whether the receptors were trapped inside the cells. 
Once activated by agonists, hPAR1 would couple to multiple G-proteins to transduce 
signals in different pathways and subsequently result in several downstream 
intracellular alterations. Transient elevations of intracellular calcium following PAR1 
activation is mediated via the Gq/11 family (Verrall et al., 1997). hPAR1C387A and 
hPAR1C388A gave similar agonist concentration effect curves to that of wt-hPAR1, but 
hPAR1C387AC388A displayed a complete shut-off of calcium signalling. However, 
the lack of calcium signalling by the double mutant could be attributed to its low 
expression. To eliminate this possibility, the low wt-hPAR1 which has similar 
expression to hPAR1C387AC388A was assessed for functionality. The calcium 
response of low wt-hPAR1 was concentration dependent reaching the maximum 40% 
of calcium ionophore. Thus, the lack of calcium signalling of hPAR1C387AC388A 
would be caused by the deficiency of putative palmitoylation sites. In addition, 
hPAR1C411A showed similar activity to couple to calcium with wt-hPAR1 in response 
to both agonists. Taken together, it suggests that cysteine 411 does not have an impact 
on calcium signalling, but cysteines 387 and C388 do influence hPAR1-Gq/11 triggered 
calcium signalling. Moreover, although there is some slight variation in the EC50 
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values for thrombin and TFLLR evoked responses in wt-hPAR1, hPAR1C387A, 
hPAR1C388A and hPAR1C411A cell lines, comparisons over the entire concentration 
effect curves shows no statistically significant difference. 
One possible explanation for the lack of calcium signalling by hPAR1C387AC388A 
could be phosphorylation of the receptor. After activation, hPAR1 is desensitised by 
rapid GRK-phosphorylation at the C-terminus (Paing et al., 2004). 
hPAR1C387AC388A may expose the otherwise hidden phosphorylation sites or 
increase the accessibility of phosphorylation sites to GRKs in the absence of the 
palmitate anchor. Thus, hPAR1C387AC388A would be highly phosphorylated so that it 
is unable to couple Gq/11 protein thereby resulting in no fluctuation of intracellular 
calcium. A human β2-adrenergic receptor lacking the palmitoylated cysteine 341 has 
been revealed to be highly phosphorylated under basal conditions and the receptor is 
unresponsive to agonist (Moffett et al., 1993). However, either one of the two cysteines 
would replace the function of the hPAR1 palmitoylation and lead to the coupling of 
Gq/11 protein. A study in endothelin receptor B concludes that palmitoylation of at least 
one of the three cysteines is required for the G protein coupling, regardless of the G 
protein subtypes (Okamoto et al., 1997). 32Pi labelling receptor phosphorylation assay 
would be used to evaluate whether mutant receptors are highly phosphorylated. 
PAR1 7-8-1 activation mechanism could be the other possible reason for the incapacity 
of hPAR1C387AC388A in calcium signalling. The 8th helix of PAR1 interacts with the 
transmembrane domain 7 and the intracellular loop 1 to form a H-bonding and ionic 
network (Swift et al., 2006). This connection is needed for PAR1-Gq signal transference. 
However, there are not putative palmitoylation sites in hPAR1C387AC388A. Thus the 
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mutant receptor prevents the formation of the 8th helix, in turn loses the connection of 
7-8-1 activation mechanism and consequently is unable to couple to Gq protein to 
trigger calcium signalling. Either one of the two cysteines could still maintain the 
formation of the hPAR1 8th helix and restore hPAR1-Gq coupling capacity. Therefore, 
hPAR1C387A and hPAR1C388A displayed similar responses to agonists seen with wt- 
hPAR1 in calcium signalling. 
In addition, hPAR1 not only can couple to the Gq/11 family, but also the Gi family and 
G12/13 family (Hollenberg and Compton, 2002). Evidence is emerging that 
palmitoylation selectively affects specific signal transduction pathways without 
affecting others. For example, the palmitoylation-deficient endothelin receptor A 
receptor fails to couple to Gq but can efficiently couple to Gs (Horstmeyer et al., 1996). 
The first palmitoylated cysteine (three cysteines) in endothelin receptor B is required 
for coupling with Gi but not for Gq (Okamoto et al., 1997). Therefore, our results only 
suggest that palmitoylation plays an important role in coupling to Gq/11, whether 
palmitoylation of hPAR1 affect other G protein coupling is still unknown. 
 
 
 
 
 
 
 
 
 
  70
 
 
 
 
 
 
THE ROLE OF C-TERMINAL 
CYSTEINES IN ERK1/2 
SIGNALLING 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 
  71
4 The role of C-terminal cysteines in ERK1/2 
signalling 
4.1 Introduction 
Extracellular signal-regulated kinases 1 and 2 (ERK1/2), known as classical MAP 
Kinases, play a critical role in cell proliferation and differentiation. ERK1/2 are 
proteins of 44 and 42 kDa respectively and share nearly 85% amino acid homology 
(Sugden and Clerk, 1997, Pearson et al., 2001). In the ERK1/2 phosphorylation 
cascade, MEK1 and MEK2 are two direct upstream activators for ERK1/2 and the 
MEKKs lying above MEK1/2 are Raf-1 isoforms (Sugden and Clerk, 1997, Pearson et 
al., 2001). GPCRs can couple to at least three G protein subfamilies (Gq/11, Gi/o, Gs) to 
trigger the ERK1/2 activation via different signal pathways and some receptors are 
able to activate more than one class of G protein. The mechanisms employed by these 
receptors are widely varied and cell type specific, but generally include modulation of 
Raf-1 isoforms activity (Pearson et al., 2001, Luttrell, 2002). The G proteins that have 
been studied in most detail with respect to the regulation of ERK1/2 are Gq/11 and Gi. 
In Gi protein triggered ERK1/2 activation, the βγ complex is believed to be the active 
signal transducer rather than the α subunit (Koch et al., 1994). In COS-7 cells 
transfected with a mutants Gi α subunit that is constitutively active, no ERK1/2 
activation occurred, however, the overexpression of βγ complex are sufficient to 
activate ERK1/2 (Faure et al., 1994). Gi βγ complex stimulates ERK1/2 activation 
through the interaction between the monomeric G protein Ras and Raf-1 isoforms. Gi 
βγ complex activates nonreceptor tyrosine kinases such as the Src family, which may 
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interact with receptor tyrosine kinase or focal adhesion kinase, and in turn recruit the 
adaptor protein Shc (Pearson et al., 2001, Luttrell, 2005). Subsequently, Shc binds to 
and activates the growth-factor-receptor binding protein 2 (Grb2), which in turn recruit 
the Ras guanine nucleotide exchange factor, mammalian Son of sevenless (mSos), 
resulting in the exchange of GDP for GTP on Ras (Pearson et al., 2001, Luttrell, 2005). 
Activated Ras then phosphorylates Raf-1 to initiate ERK1/2 cascade. Moreover, 
phosphatidylinositide-3 kinase (PI-3 kinase), a heterodimeric enzyme consisting of a 
110 kDa (p110) subunit that can be directly activated by Giβγ subunits but not α 
subunits, and a receptor tyrosine kinase associated 85 kDa (p85) subunit, functions as 
an intermediate in the Giβγ proteins induced activation of ERK1/2 in some cell types 
(Takeda et al., 1999, Bocker and Verspohl, 2001, Touhara et al., 1995, Lopez-Ilasaca et 
al., 1997). Gq/11 triggered ERK1/2 activation is often a PKC-dependent process through 
a Ras-dependent or Ras-independent pathway (Pearson et al., 2001). After Gq/11 
activation, Gq/11 α subunit activates PLC and leads to the generation of IP3 and DAG as 
described previously. DAG can activate PKC which in turn regulates Raf-1 through 
direct phosphorylation and eventually activates ERK1/2 independent of Ras (Pearson 
et al., 2001), whereas the intracellular Ca2+ release as a result of IP3 production, would 
activate the Shc-Grb2-mSos complex and stimulate ERK1/2 via a Ras-dependent 
pathway (Luttrell, 2002).  
PAR1 is able to couple with Gq/11 and Gi/o in several cells. Although the ERK1/2 
regulation induced by PAR1 is not fully understood, PAR1 has been shown to 
incorporate many components of the model of GPCR induced ERK1/2 activation via 
Gq/11 and Gi/o (Macfarlane et al., 2001). PAR1-AP was found to rapidly activate the 
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p21ras which is a 21 kDa mammalian Ras protein in the CCL39 fibroblasts, and the 
activation was inhibited by the treatment of pertussis toxin, a Gi protein inhibitor and 
genistein, a tyrosine kinase inhibitor, indicating a Gi protein and a tyrosine kinase are 
involved in mediating the activation of ERK1/2 via PAR1 (van Corven et al., 1993). 
The study in astrocytes has shown that PAR1 activation of ERK1/2 depends on two 
branches: one is mediated by Giβγ subunit and PI-3 Kinase, and the other is mediated 
by Gq and PKC (Wang et al., 2002). ERK1/2 phosphorylation in human colon cancer 
cells was induced by PAR1 through the Src phosphorylation and the transactivation of 
epidermal growth factor receptor which is a receptor tyrosine kinase (Darmoul et al., 
2004). This result is consistent with that in cardiac fibroblast, PAR1 mediated ERK1/2 
activation requires Src family kinase and EGFR transactivation (Sabri et al., 2002). 
Additionally, thrombin has been shown to stimulate cell proliferation through 
activation of Ras/Raf-1/MEK1/2/ERK1/2 pathway in tracheal smooth muscle cells 
which express PAR1 and PAR2 proteins, and the activation was regulated by PKC, Ca2+, 
PLC, PI-3 kinase and tyrosine kinase (Lin et al., 2002). In CCL2 fibroblast, PKC and 
Raf-1 have been indicated to involve in the PAR1-Gq triggered ERK1/2 pathway (Deng 
et al., 2008).  
Aims 
This section of the study attempts to determine the effect of hPAR1 putative 
plamitoylation sites—C387 and C388 in the hPAR1 triggered ERK1/2 signalling. 
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4.2 Reagents and methods 
4.2.1 Reagents 
Phospho-p44/42 MAP kinase (Thr202/Tyr204) antibody and p44/42 MAP kinase 
antibody were purchased from Cell Signalling, New England Biolabs, Hitchin, 
Hertfordshire, UK. ECL western blotting detection reagents and anti-rabbit IgG 
horseradish peroxidase-linked whole antibody (from donkey) were purchased from 
Amersham Biosciences, Buckinghamshire, UK. RestoreTM western blot stripping 
buffer was supplied by Pierce, Northumberland, UK. Immun-Blot® PVDF membrane 
were supplied by Bio-Rad laboratories, Inc, Hertfordshire, UK. All other chemicals 
and reagents were purchased from Sigma-Aldrich, Poole, Dorset, UK.  
 
4.2.2 Methods 
Cells were grown in 6 well plates to ~80% confluence and incubated in serum-free 
medium overnight. The effect of increasing agonist concentration on MAPK signalling 
was investigated by incubation with—either thrombin (0.001-3 U/ml) or TFLLR 
(0.01-31.6 μM) for 5 min. In time course experiments, cells were also challenged with 
either 0.1 U/ml thrombin or 1 μM TFLLR at different time points (0, 2 min, 5, 10, 20, 
30, 60, 120, 240). Treatment of cells with 10% FCS for 5 min was used as a positive 
control in each experiment. The treatment was halted by removal of media and direct 
addition of 350 μl of Laemmli’s buffer (2% SDS, 10% glycerol, 50 mM Tris-HCl 
(pH6.8), 5 mM EDTA, 0.008% bromophenol blue and 5% β-ME). The cell lysates 
were subsequently transferred into 1.5 ml centrifuge tubes and centrifuged at 14,000 g 
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at 4˚C for 10 min. The samples were then incubated at 4˚C for 20 min with 0.025 U 
benzonase with end over end mixing to degrade the DNA. The benzonase treated 
samples were then heated at 100˚C for 5 min and stored at -80˚C until analysis. 
The samples were equally loaded and run on a 10% SDS polyacrylamide gel (see table 
4.2) in electrode buffer consisting of 25 mM Tris base, 200 mM Glycine and 0.1%(w/v) 
SDS to separate proteins. The sample proteins were transferred from the gel to 
polyvinylidene difluoride (PVDF) membrane in blotting buffer containing 25 mM Tris 
base, 200 mM Glycine, and 20% methanol. A quick reversible Ponceau S (0.25% (w/v) 
Ponceau S in 5% acetic acid) staining was performed to check the success of protein 
blotting. The stain was then removed by a quick rinse with dH2O. 
Reagents Stacking Gel 10% SDS polyacrylamide gel 
Acrylamide solution 1.3 ml 3.33 ml 
dH2O 6.1 ml 4.02 ml 
Tris-HCl pH6.8, 2.5 ml pH8.8, 2.5 ml 
10%SDS 100 μl 100 μl 
10%APS 50 μl 50 μl 
TEMED 20 μl 5 μl 
Table 4.2, Reagents used to make a SDS-PAGE 
Once the protein transfer was completed, the membranes were blocked by 5%(w/v) 
non-fat milk in PBS/0.1% Tween-20 for 1 hour, followed by incubating with 
phospho-P44/42 MAP kinase antibody (1 in 1000 dilution) in 5% BSA, PBS/0.1% 
Tween-20 overnight at 4˚C. After washing in PBS/0.1%Tween-20 4×15 min, the 
membranes were probed with anti-rabbit IgG HRP-linked antibody (1 in 1000 dilution) 
in PBS/0.1% Tween-20 2% non-fat milk for 60 min at RT. The membranes were then 
washed again 4×15 min in PBS/0.1%Tween-20 before applying by ECL western 
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blotting detection reagents. The membranes were photographed using a UVP 
Laboratory Products Epichem II Darkroom setup to measure chemiluminescence. 
The antibodies were stripped from the membranes using RestoreTM western blot 
stripping buffer for 2 hours at 37˚C 200 rpm. Subsequently, the membranes were 
reprobed with total P44/42 MAP kinase antibody overnight at 4˚C. The membranes 
were then washed, incubated with secondary antibody and visualized as described 
above. 
 
4.3 Results  
To characterise the effect of deleted cysteines on hPAR1 ERK1/2 (P44/42) MAPK 
signalling, agonist triggered MAPK signalling assays were carried out in a 
dose-dependent and time-dependent manner. EV, wt-hPAR1 and hPAR1C387AC388A 
were rendered quiescent for 18 hours prior to stimulation with the different 
concentrations of an agonist—either thrombin (0.001 U/ml to 3 U/ml) or TFLLR (0.01 
µM to 31.6 µM) for 5min. 10% FCS treatment was utilised as a positive control to 
stimulate the phosphorylation of P44/42 for 5 min. 
The band intensity rapidly increased after the addition of 0.03 U/ml thrombin or 1 µM 
TFLLR in the wt-hPAR1 phosphorylated P44/42 blot, but there was no obvious 
fluctuation in band intensity in the EV and hPAR1C387AC388A phosphorylated 
p44/42 blot (Fig 4.3.1a and 4.3.2a). Figure 4.3.1b shows that 0.03 U/ml thrombin was 
sufficient to trigger a robust increase in phosphorylated P44/42 in wt-hPAR1 
expressing cells, with maximum phosphorylated P44/42 seen by 0.1 U/ml, however 
there was no significant increase seen in EV or hPAR1C387AC388A. Figure 4.3.2b 
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shows a TFLLR concentration dependent increase in phosphorylated P44/42 for 
wt-hPAR1, plateauing after 1 µM. In comparison, the hPAR1C387AC388A triggered 
MAPK activation curve has a gradual but smaller increase and reached the maximal 
response at the higher concentration of 31.6 µM, however, the EV triggered MAPK 
activation curve has a even smaller increase (Fig 4.3.2b). There is not significant 
difference between EV and hPAR1C387C388A in MAPK activation curve in response 
either thrombin or TFLLR (P>0.05).  
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Figure 4.3.1, Thrombin stimulated ERK1/2 phosphorylation. a) Western blots for 
EV, wt-hPAR1 and hPAR1C387AC388A cells treated with increasing thrombin 
concentrations. The upper rows are the blots probed with anti-phosphorylated P44/42 
antibody and the lower rows are the blots re-probed with anti-total P44/42. 10% FCS 
was used as a positive control. The blots shown are representative of 3 repeats.b) 
Graphs showing densitometric values for bands produced by western blots. Values are 
expressed as a percentage of total P44/42 and then normalised to no treatment. The 
results are expressed as the means ± S.E. from 3 separate experiments. 
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Figure 4.3.2 TFLLR stimulated ERK1/2 phosphorylation. a) Western blots for EV, 
wt-hPAR1 and hPAR1C387AC388A cells treated with increasing TFLLR 
concentrations. The upper rows show the blots probed with anti-phosphorylated P44/42 
antibody and the lower rows are the blots re-probed with anti-total P44/42. 10% FCS 
was used as a positive control. The blots shown are a representation of 3 repeats.b) 
Graphs showing densitometric values for bands produced by western blots. Values was 
expressed as a percentage of total P44/42 and then normalised to no treatment. The 
results present the means ± S.E. from 3 separate experiments. 
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EV, wt-hPAR1 and hPAR1C387AC388A were then treated with either 0.1 U/ml 
thrombin or 1 µM TFLLR over a period of 240 min. 10% FCS was utilised as a 
positive control to stimulate the phosphorylation of P44/42 at 5 min. Thrombin 
stimulated the phosphorylation of P44/42 through wt-hPAR1 activation reaching the 
maximal activity at 5 min, and then gradually returned to the basal level by 240 min 
(Fig 4.3.3b). However, thrombin induced MAPK activation through either EV or 
hPAR1C387AC388A has no clear fluctuation during 240 min (Fig 4.3.3b). Similarly, 
TFLLR triggered MAPK activation through wt-hPAR1 activation producing a rapid 
increase in the first 5 min reaching a plateau, then decreasing after 60 min (Fig 4.3.4b). 
TFLLR triggered MAPK activation through either EV or hPAR1C387AC388A with a 
slow rise in the first 20 min returning to basal levels, and then increasing again after 60 
min (Fig 4.3.4b). The statistical analysis shows that there is no significant difference 
between EV and hPAR1C387AC388A triggered MAPK signalling time course in 
response to either thrombin or TFLLR (P>0.05). 
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Figure 4.3.3 Thrombin stimulated ERK1/2 phosphorylation in a time course. a) 
Western blots for EV, wt-hPAR1 and hPAR1C387AC388A cells treated with 0.1 U/ml 
thrombin at different time points. The upper rows are the blots probed with 
anti-phosphorylated P44/42 antibody and the lower rows are the blots re-probed with 
anti-total P44/42. 10% FCS was used as a positive control. The blots shown are a 
representation of 3 repeats.b) Graphs showing densitometric values for bands produced 
by western blots. Values are expressed as a percentage of total P44/42 and then 
normalised to no treatment. The results present the means ± S.E. from 3 separate 
experiments. 
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Figure 4.3.4, TFLLR stimulated ERK1/2 phosphorylation in a time courese. a) 
Western blots for EV, wt-hPAR1 and hPAR1C387AC388A cells treated with 1µM 
TFLLR at different time points. The upper rows are the blots probed with 
anti-phosphorylated P44/42 antibody and the lower rows are the blots re-probed with 
anti-total P44/42. 10% FCS was used as a positive control. The blots shown are a 
representation of 3 repeats.b) Graphs showing densitometric values for bands produced 
by western blots. Values are expressed as a percentage of total P44/42 and then 
normalised to no treatment. The results present the means ± S.E. from 3 separate 
experiments. 
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4.4 Discussion 
The results in this section show that hPAR1C387AC388A was unable to trigger agonist 
induced activation of ERK1/2 in a dose-dependent manner and time course as 
wt-hPAR1. It is partially consistent with the study in the palmitoylation-deficient V2 
vasopressin. The mutant receptor displayed a delayed and decreased agonist triggered 
ERK1/2 activation (Charest and Bouvier, 2003). However, palmitoylation was shown 
to have a contrary impact on hPAR2, palmitoylation-deficient mutant triggered greater 
and more prolonged ERK1/2 activation in response to agonists (Botham, 2007). The 
lack of ERK1/2 signalling in hPAR1C387AC388A could be due to the uncoupling of 
palmitoylation-less hPAR1-G protein. As hypothesized in section 3.4, 
hPAR1C387AC388A would be highly phosphorylated leading to the failure of coupling 
to G protein. Both Gq and Gi proteins have been shown to be involved in ERK1/2 
activation by PAR1 in different cell types. However, the mechanisms employed by 
GPCRs in ERK1/2 activation are varied and cell specific. It is difficult to conclude that 
the lack of ERK1/2 signalling is caused by the deficiency in hPAR1-Gq coupling, 
hPAR1-Gi coupling or both in KNRK cells. PAR1 7-8-1 activation mechanism is 
required for PAR1-Gq coupling, but whether this mechanism is also essential for the 
coupling to other G proteins is still unknown (Swift et al., 2006). G protein inhibitor 
would be used to determine which signalling pathway PAR1 use to trigger ERK1/2 
activation in KNRK, and hPAR1C387A and hPAR1C388A would be analysed to 
investigate the role of single cysteine in the hPAR1 induced ERK1/2 signalling. 
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5 The role of C-terminal cysteines in agonist 
triggered receptor internalisation  
5.1 Introduction 
Following activation, most GPCRs are rapidly phosphorylated by GRKs leading to 
β-arrestin binding which subsequently recruits clathrin and adaptor protein complex-2 
(AP2). Receptors are then internalised via clathrin-coated pits mediated by dynamin to 
endosomes. Dynamin is a GTPase that regulates the detachment of clathrin-coated pits 
from the plasma membrane (Wolfe and Trejo, 2007). PAR1 as a GPCR member has also 
been reported to utilize a clathrin and dynamin dependent pathway for receptor 
internalization upon activation (Trejo et al., 2000, Paing et al., 2002). Activated PAR1 is 
rapidly recruited to clathrin-coated pits and the internalisation is inhibited in dynamin 
and clathrin mutants (Trejo et al., 2000). Apart from the agonist triggered receptor 
internalisation, PAR1 internalises constitutively between the cell surface and an 
intracellular compartment in the absence of a ligand. However, β-arrestins which are 
essential for internalisation of many GPCRs are not required by either type of PAR1 
internalisations. In the mouse embryonic fibroblasts (MEFs) derived from β-arrestin 
knockouts, activated PAR1 was internalised similarly with wild type via a clathrin and 
dynamin dependent pathway, and constitutive internalisation also remained intact (Paing 
et al., 2002). Coexpressing of PAR1 and β-arrestin in COS-7 cells also failed to enhance 
PAR1 internalisation induced by agonist (Chen et al., 2004). Clathrin adaptor AP2 and 
its binding site tyrosine-base motif YXXL within the C-tail are required for constitutive 
PAR1 internalisation, but not agonist triggered internalisation. In HeLa cells depleted of 
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AP2 by RNA interference, the non-activated receptor failed to constitutively internalise 
and accumulate in the intracellular store, in contrast, activated receptor internalised 
irrespective of siRNA treatment (Paing et al., 2006). However, activated PAR1 
internalisation still occurred through a clathrin and dynamin dependent pathway in AP2 
depleted cells (Paing et al., 2006). There are two tyrosine-based motifs Y383SIL386 and 
Y420KKL423 found in the C-tail of PAR1. The replacement of tyrosine 383 and leucine 
386 by alanines caused a significant impairment in agonist triggered PAR1 
internalisation, but did not affect the constitutive internalisation of unactivated PAR1 
(Paing et al., 2004). However, this group reported that the PAR1 A383SIA386 mutant 
exhibited levels of constitutive and agonist induced internalization similar to wild-type 
two years later (Paing, 2006). The other tyrosine-based motif Y420KKL423 has been 
indicated to directly interact with AP2 and be critical to PAR1 constitutive 
internalization, but not agonist activated receptor internalisation (Paing et al., 2006). 
Taken together, it suggests that PAR1 may utilize distinct molecular machinery in 
regulating constitutive internalisation and agonist induced internalisation. Recently, a 
study indicated that ubiquitination, a covalent attachment of ubiquitin to a protein, 
negatively regulates constitutive PAR1 internalisation, and K421 and K422 located within 
the C-tail tyrosine-based motif are the major sites of ubiquitination (Wolfe et al., 2007). 
Constitutive internalisation of ubiquitin-deficient PAR1 was significantly increased and 
inhibited by the fusion of ubiquitin to the C-tail (Wolfe et al., 2007). Interestingly, AP2 
was required for the agonist triggered ubiquitin-deficient receptor internalisation, unlike 
the activated wild-type receptor that is internalised independent of AP2 (Wolfe et al., 
2007).  
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The role of β-arrestin, AP2, tyrospin-based motif in the PAR1 C-tail and ubiquitination 
in PAR1 internalisation has been well studied. However, the relationship between 
palmitoylation and PAR1 internalisation is still unclear. Here, flow cytometry was used 
to asses the rate and the extent of receptor internalisation following agonist 
stimulation. 
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Figure 5.1, Modes of PAR1 internalisation. a) Constitutive internalisation, intact 
PAR1 cycles between the plasma membrane and the intracellular store by a clathrin, 
dynamin and AP2 mediated mechanism. b) Agonist triggered internalisation using a 
clathrin and dynamin dependent pathway, activated PAR1 is then degraded in the 
lysosome. 
 
 
Aims 
The aim of the study in this chapter is to investigate the effect of hPAR1 putative 
plamitoylation sites—C387 and C388 in the agonist triggered receptor internalisation. 
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5.2 Materials and Methods 
5.2.1 Materials and reagents 
All the reagents and chemicals used here are described in section 2.2. 
 
5.2.2 Methods 
5.2.2.1 Construction of hPAR1R41A DNA and hPAR1R41A expressing cell line 
The KNRK cell line expressing hPAR1R41A in which the arginine located at 41 in the 
N-terminal was replaced with an alanine was generated as described in section 2.3. 
Briefly, the mutant DNA construction was produced by mutagenic PCR using the 
following primers and wt-hPAR1 in pcDNA3.1 vector as a DNA template. 
R41A primers 
5’-GCC ACC TTA GAT CCC GCG TCA TTT CTT CTC AGG-3’ 
3’-CGG TGG AAT CTA GGG CGC AGT AAA GAA GAG TCC-5’ 
 
Then, KNRK cells were transfected with the amplified and purified hPAR1R41A DNA 
and taken through single cell cloning. FACS and calcium signalling assay were 
employed to pick up the best hPAR1R41A expressed cell line out of ~40 colonies. 
 
5.2.2.2 Flow cytometry detection of PAR1 internalisation 
Cells were harvested from 75 cm2 flasks then divided into 5 ml falcon tubes (~30000 
cells per tube) before centrifugation at 3000 g at 4˚C for 5 min. Cell pellets were 
resuspended in 300 μl of ice-cold CAB. The agonist (either 10 U/ml thrombin or 50 
μM TFLLR) was added to the cells at the different time points (0, 30 sec, 1, 5, 10, 20, 
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40 min for wild type and mutant PAR1 cell lines, 0 and 40 min for EV-KNRK) and 
mixed well before incubation at 37˚C with gentle orbital shaking (100 rpm) for the 
time specified. The cells were then placed on ice for 5 min and centrifuged at 3000 g at 
4˚C for 5 min. Receptor expression was then assessed by FACS as described in section 
2.3.2.4. The percentage of receptors on the cell surface was calculated using the mean 
of the fluorescence level and this way plotted to represent a receptor internalisation. 
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5.3 Results 
5.3.1 Generation of hPAR1R41A expressing cell line 
Thrombin recoginizes the LDPR41/S42 in the N-terminal of hPAR1 and cleaves the 
peptide bond between arginine and serine to activate hPAR1, whereas TFLLR binds to 
the ECL2 of hPAR1 directly to activate the receptor without interacting with the 
N-terminus. Since the alanine substituted for the arginine41 in hPAR1, thrombin is 
believed to be incapable of recognising/cleaving the receptor, but TFLLR is still able to 
activate the receptor. The hPAR1R41A expressing cell line was successfully generated 
and screened by FACS and calcium signalling assay. The results are shown in Figure 
5.3.1. hPAR1R41A has a clear rightward shift compared to EV-KNRK (Fig 5.3.1a). 
Figure 5.3.1 b and c display that hPAR1R41A triggered intracellular calcium signalling 
in response to TFLLR and calcium ionphore, but failed to respond to the other hPAR1 
agonist—10 U/ml thrombin.  
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Figure 5.3.1, FACS analysis and calcium imaging of hPAR1R41A. (a) FACS trace 
of hPAR1R41A cell surface expression against EV-KNRK. hPAR1R41A is shown as a 
green line and EV-KNRK is shown as solid purple. (b) Intracellular calcium 
mobilisation in hPAR1R41A after agonist activation and addition of calcium ionphore. 
 
 
 
 
EV 
hPAR1R41A 
(a) 
(b) hPAR1R41A
0 25 50 75 100 125 150
210000
230000
250000
270000
290000
310000
330000
Time (sec)
Fl
uo
re
sc
en
ce
 (A
U
)
 
Calcium 
ionphore 
(2µM) 
(c) hPAR1R41A
0 50 100 150 200 250
150000
170000
190000
210000
230000
250000
270000
Time (sec)
Fl
uo
re
sc
en
ce
 (A
U
) TFLLR 
(50µM) 
Calcium 
ionphore 
(2µM) Thrombin 
(10U/ml) 
  93
5.3.2 Agonist triggered receptor internalisation 
hPAR1 internalisation in response to TFLLR and thrombin are shown in Figure 5.3.2. 
Internalisation was determined by the agonist-promoted decrease in cell surface 
immunoreactivity against hPAR1. After the agonist treatment for different time period, 
the treated cells were placed on ice for 5 min in order to stop the receptor 
internalization from the cell surface. The remaining hPAR1 receptors on the cell 
surface were then labelled with anti-PAR1 antibody and further analysed at 4˚C. 
All the cell lines internalised after treatment with 10 U/ml thrombin except 
hPAR1R41A. For wild type and C-terminal cysteine mutant hPAR1 cell lines, thrombin 
triggered internalisation of approximately 50% of the receptor in the first 30 sec 
reaching a maximal internalisation of 70% by 20 min, and thereinto 
hPAR1C387AC388A has the fastest internalisation rate (Fig 5.3.2a). The wt-hPAR1 
failed to internalise by 40 min of 50 µM TFLLR treatment (Fig 5.3.2b). However, all 
mutant hPAR1 cell lines internalised in response to TFLLR including hPAR1 R41A 
reaching maximal internalisation of 60% by 40 min (Fig 5.3.2b). Seventy percent of 
TFLLR treated hPAR1C387A and hPAR1C388A remained at the surface after 10 min 
(Fig 5.3.2b). The internalisation rate of hPAR1C387AC388A is slower than that of the 
other mutant cell lines, but the maximal internalisation levels are similar after 40 min 
(Fig 5.3.2). In general, thrombin triggered internalisation more rapidly and to a greater 
extent compared to TFLLR (compare Fig 5.3.2a and b). 
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Figure 5.3.2, Agonists triggered receptor internalisation. a) The percentage of either 
wild type or mutant hPAR1 receptors left on the cell surface after the treatment of 10 
U/ml thrombin at different time points. b) The percentage of either wild type or mutant 
hPAR1 receptors left on the cell surface after the treatment of 50 μM TFLLR-NH2 at 
different time points. The results represent the means ± S.E. from three experiments 
performed in duplicate.  
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5.4 Discussion 
The results in this section shows that in agonist triggered internalisation, hPAR1C387A, 
hPAR1C388A and hPAR1C387AC388A all internalised in response to thrombin and 
TFLLR, except for wt-hPAR1 which only internalised in response to thrombin. The 
thrombin recoginition site deficient mutant hPAR1R41A as expected failed to 
internalise following thrombin treatment, but internalised with TFLLR.  
The role of palmitoylation in regulating GPCR internalisation varies. It has been 
reported that lacking palmitoylation sites can lead to an increase, a decrease or even no 
affect on receptor internalisation in different GPCRs. For example, an unpalmitoylated 
CCR5 mutant does not influence the receptor internalisation (Blanpain et al., 2001), 
while an unpalmitoylated human β2-adrenergic receptor mutant increases the receptor 
internalisation (Moffett et al., 1993), and an unpalmitoylated human bradykinin B2 
receptor has a 30% reduction in the internalisation capacity (Pizard et al., 2001).  
There is no remarkable difference among the thrombin triggered internalisation rate of 
wt-hPAR1, hPAR1C387A, hPAR1C388A and hPAR1C387AC388A. Surprisingly, 
wt-hPAR1 treated with TFLLR failed to internalise, but TFLLR triggered 
internalisation occurred in all mutant cell lines. Therefore, a KNRK cell line 
expressing the mutant hPAR1R41A which lacks the thrombin recoginition site was 
generated and utilized as a control. This mutant would be unable to be recognised by 
thrombin and thus can not be activated, but TFLLR can still activate it by direct 
binding to the mutant receptor. As expected hPAR1R41A internalised following 
TFLLR treatment but not thrombin. However, unlike wt-hPAR1 hPAR1R41A 
internalised with TFLLR treatment. It may suggest the R41 is critical for the hPAR1 
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internalisation, the existence of R41 disrupt the agonist-induced receptor 
internalisation. The internalisation would take place only when R41 is removed by 
either thrombin or a point mutation. Thrombin and TFLLR may utilize different 
mechanisms to promote hPAR1 internalisation in the KNRK cell system. TFLLR as an 
intermolecular PAR1 peptide agonist does not activate the PAR1 in the same 
mechanism as thrombin (Blackhart et al., 2000, Swift et al., 2006). The receptor 
conformational change induced by TFLLR binding may not be sufficient to trigger the 
depalmitoylation or internalisation of wt-hPAR1. It may also explain why 
thrombin-induced internalisation is more efficient than TFLLR. hPAR1C387A and 
hPAR1C388A have a weaker palmitoylation anchor and thus would still 
depalmitoylate/internalise with TFLLR. As a result, the data may suggest that both 
R41A and palmitoylation are important in TFLLR-triggered hPAR1 internalisation. 
Additionally, it needs to be noted that PAR1AP doesn’t lead to receptor internalisation 
which may be due to the specific peptide used in this study—TFLLR. 
In the thrombin triggered internalisation, as hypothesized in section 3.4, either one of 
the two cysteines would restore the palmitoylation function, thus hPAR1C387A and 
hPAR1C388A have the same internalisation rate as wt-hPAR1. Interestingly, 
hPAR1C387AC388A displayed a faster internalisation rate compared to wt-hPAR1. The 
removal of the C-terminus region including palmitoylation sites of PAR1 resulted in 
constitutive receptor internalisation in a agonist-independent manner (Paing et al., 
2004), which would be caused by excessive phosphorylation of the 
palmitoylation-deficient receptors. Thus, hPAR1C387AC388A would internalise 
constitutively and accordingly exhibited a low cell surface expression. The small 
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amount of the receptors expressed on the cell surface would be activated and further 
internalised after thrombin treatment. As a result, the internalisation rate of 
hPAR1C387AC388A was faster than wt-hPAR1 in the first 30 sec as shown in Figure 
5.3.2.  
Immunofluorescence microcopy has been utilized to attempt to give a detailed image 
of agonist-triggered internalisation on an individual cell, but the laser bleach out the 
fluorescent staining in a few seconds. If time had permitted, the technique would be 
improved or new technique would be employed. 
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6 The role of C-terminal cysteines in hPAR1 
palmitoylation 
6.1 Introduction 
Palmitoylation is one of the most common post-translational modifications occurring 
in proteins. A 16 carbon palmitic acid is covalently attached via a thioester bond to 
cysteine residues of the targeting protein, associating it with the plasma membrane. 
The reaction is catalysed by palmitoyl transferases (PATs). 
 
 
 
 
 
 
 
 
Figure 6.1, Protein palmitoylation process. 
 
This covalent attachment of palmitic acid is reversible. The rapid palmitic acid 
turnover (depalmitoylation) has been observed in vivo and is mediated by 
palmitoyl-thiolesterases (APTs) (Escriba et al., 2007). In a variety of GPCRs, an 
increase in the palmitate turnover rate has been detected in response to extracellular 
agonist stimulation. For example, the pretreatment of β2-adrenergic receptor with 
agonist resulted in a dramatic (~80%) decrease in the [3H] palmitate incorporation 
(Loisel et al., 1996). The half-life of the β2-adrenergic receptor-bound palmitate was 
Cysteine residue Palmitoyl CoA
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reduced 1.8 fold after the agonist stimulation without affecting the turnover rate of the 
receptor itself (Loisel et al., 1996).  
The most frequently used experimental approach to demonstrate if a protein is 
palmitoylated is to chemically dissociate radio-labelled palmitate from the protein 
using dithiothreitol or hydroxylamine at a neutral pH (Qanbar and Bouvier, 2003). 
Here, cells were labelled with [3H] palmitic acid, the hPAR1 receptors were 
immunoprecipitated using anti-HA11 antibody and then analysed on SDS-PAGE to 
represent [3H] palmitic acid incorportaion. Unfortunately the immunoprecipitation 
using HA11 epitope failed to precipitate the receptors from hPAR1 cell lines. However, 
fusing enhanced yellow fluorescent protein (eYFP) after HA11 epitope at the end of 
hPAR1 receptors restored the ability of HA11 binding (Figure 6.2). Thus the wild type 
and mutant hPAR1 were regenerated with eYFP. 
 
 
 
 
 
 
 
Figure 6.2, Representative model of hPAR1eYFP. Wild type hPAR1eYFP 
(POMC-M1-hPAR1-HA11-eYFP) possessed an N-terminal POMC singal peptide 
followed by an M1 epitope, a HA11 epitope was fused to the C-terminal tail followed 
by an enhanced yellow fluorescent protein. See Appendix for DNA sequence and 
protein sequence. 
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Aims 
This section of the study attempts to determine whether cysteines 387, 388 in the 
C-terminus of hPAR1 are palmitoylated.  
 
6.2 Materials and methods 
6.2.1 Reagents and materials 
Primers were purchased from MWG Biotechnology, Ebersberg, Germany. 1Kb DNA 
ladder was purchased from Invitrogen, Paisley, UK. ACCUZYMETM DNA polymerase 
and 10×AccuBuffer were purchased from Bioline, London, UK. Restriction 
endonucleases XhoI and BamHI were purchased from New England Biolabs, Hithchin, 
Hertfordshire, UK, along with their specific NEBuffer 3 (10×). The rapid DNA ligation 
kit was supplied by Roche, East Sussex, UK. QIAquick® gel extraction kit was 
supplied by Qiagen, Crawley, West Sussex, UK. pEYFP vector was supplied by BD 
biosciences clontech, Erembodegem,Belgium. PageRulerTM plus prestained protein 
ladder was obtained from Fermentas, York, UK. M-PER® mammalian protein 
extraction reagent was obtained from Pierce, Northumberland, UK. µMACs HA tagged 
protein isolation kit was purchased from Miltenyi Biotech, Bergisch Gladbach, 
Germany. Purified mouse antibody mono HA.11 was purchased from Covance, 
Berkshire, UK. Sheep anti-mouse IgG-horseradish peroxidise, [9,10(n)-3H] palmitic 
acid, AmplifyTM fluorographic reagent and HyperfilmTM MP were all supplied by 
Amersham Biosciences, Buckinghamshire, UK. All the other chemicals and reagents 
used in this chapter were the same with those in section 2.2. pcDNA 3.1 containing 
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wild type hPAR1eYFP was supplied by Dr S.J.compton. 
 
6.2.2 Methods 
6.2.2.1 Constructions of C-terminal cysteine deleted hPAR1eYFP DNAs 
(hPAR1C387AeYFP, hPAR1C388AeYFP, hPAR1C387AC388AeYFP) and 
eYFP-HA11 in pcDNA3.1 vector 
C-terminal cysteine deleted hPAR1eYFP constructs were generated as described in 
section 2.2.1.1. Briefly, the mutant DNAs were produced by mutagenic PCR using the 
same C387A, C388A, C387AC388A oligonucleotide primers (as shown in 2.3.1.1), the 
pcDNA3.1 vector containing wt-hPAR1eYFP was utilized instead as a plasmid DNA 
template.  
 
6.2.2.2 Generation of eYFP-HA11 DNA fragment 
The generation of eYFP-HA11 was performed by PCR of eYFP from the eYFP vector 
with the specific oligonucleotide primers (as below). eYFP F primer possessed an XhoI 
restriction site and a Kozak sequence prior to the start codon of the eYFP sequence. 
eYFP/HA R primer possessed a BamHI restriction site and a 24 nucleotides HA11 
sequence, which located between the stop codon and the main body of the eYFP 
sequence. Both primers were designed to terminate with several G or C bases. 
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eYFP F primer 
5’-GCG GCC CTC GAG CCA CCA TGG TGA GCA AGG GCG AGG AGC TGT TCA 
CCG GGG TGG TGC CC-3’ 
 
eYFP/HA R primer 
5’-GGC CGC GGA TCC TTA GGC ATA ATC GGG AAC ATC ATA GGG ATA CTT 
GTA CAG CTC GTC CAT GCC-3’ 
 
PCR reactions were prepared as follows; water blank was used instead of DNA 
template as a control. 
10×AccuBuffer                10% (v/v) 
eYFP vector (1 ng/μl)              0.02 ng/μl 
eYFP F (20 ng/μl)           0.4 ng/μl      
eYFP/HA R (20 ng/μl)          0.4 ng/μl 
dNTP mix                      0.5 mM 
ACCUZYMETM DNA polymerase     0.5 U/μl 
40 μl of DEPC H2O was added to reach a total volume of 50 μl. The PCR reactions 
were then placed in a thermal cycler to run the following cycles: 
Cycles Process Temperature (˚C) Time 
1 Pre-heat 95 2 min 
35 DNA denaturation 95 30 sec 
Primer Annealing 55 30 sec 
Extension 68 1 min 
1 Final extention 68 10 min 
Table 6.2.1, Conditions of PCR 
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The PCR products were run on 1.3% agarose gel alongside a 1Kb DNA ladder to allow 
the identification of band size. The eYFP-HA11 DNA fragment was isolated from the 
gel under UV light and the inclusive PCR product was extracted using QIAquick® gel 
extraction kit. 
 
6.2.2.3 Digestion and ligation of eYFP-HA11 and pcDNA3.1 vector 
pcDNA 3.1 and the PCR product were digested with XhoI and BamHI restriction 
enzymes in order to create XhoI and BamHI cohesive ends. Both XhoI and BamHI 
exhibit optimum activity at 37˚C. In a total volume of 20 μl, 5 μl pcDNA3.1 vector or 
10 μl PCR product was incubated with NEBuffer 3, BSA, XhoI, BamHI at 37˚C for 3 
hours. The vector and PCR product were then gel purified to remove the unwanted, 
cleaved portion of DNA. 
After gel purificiation, eYFP-HA11 was ligated into pcDNA3.1 using a rapid DNA 
ligation kit to generate eYFP-HA11 in pcDNA3.1. The ligation reaction contained 10 
μl of buffer, 1 μl of DNA ligase, 1 μl of pcDNA 3.1 vector, 5 μl of eYFP-HA11 and 4 
μl dH2O, and was performed at room temperature for 5min.  
 
6.2.2.4 Bacterial transformation 
Bacterial transformation was carried out as described in section 2.3.1.2. Briefly, either 
7 μl of hPAR1eYFP DNA (wild type/mutants) or 3 μl of the ligation product was 
incubated with β-ME treated XL-1 blue supercompetent E.coli, and then heat shocked 
at 42˚C. After incubating with 500 μl of LB broth at 37˚C, 200 rpm for 1 hour, the 
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E.coli was spread onto a LB agar plate containing ampicillin (100 μg/ml) and 
incubated at 37˚C overnight. 
 
6.2.2.5 Harvesting hPAR1eYFP DNAs and eYFP-HA11 in pcDNA3.1 
hPAR1eYFP DNA (wild type/mutants) and eYFP-HA11 in pcDNA3.1 were amplified, 
extracted and purified as described in section 2.3.1.3, except that XhoI and BamHI 
restrition enzymes were utilized to digest the purified DNAs in order to assess the 
presence of insert. A small amount of the sample DNAs was then sent to MWG for 
sequencing.  
 
6.2.2.5 Generation of wt-hPAR1eYFP, hPAR1C387AeYFP, hPAR1C388AeYFP, 
hPAR1C387AC388AeYFP and eYFP-HA11 permanently expressing cell lines  
The procedure was the same as that described in section 2.3.2. Briefly, KNRK cells 
were transfected with the hPAR1eYFP DNA (wild type/mutants) and eYFP-HA11 in 
pcDNA 3.1 respectively. The resulting cells were taken through two rounds of single 
cell cloning and analysed by FACS as described in section 2.3.2.4. The clone 
permanently showing the highest level of receptor expression was selected and utilised 
for further analysis. 
 
6.2.2.6 [3H] palmitic acid incorporation  
Cells were grown in T75 flasks to ~80% confluence and then incubated in serum-free 
medium overnight. Toluene containing [3H] palmitic acid was evaporated overnight 
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under vacuum. Dried [3H] palmitic acid was dissolved in DMSO. [3H] palmitate 
labelling medium was then made and comprised of DMEM, 1 mCi/3ml [3H] palmitic 
acid, 1% DMSO and 2.5% FCS. The serum-free medium was removed from the flasks 
and [3H] palmitate labelling medium was introduced to the cells. After 4 hours 
incubation at 37˚C, the [3H] palmitate labelling medium was disposed of. The cells 
were then washed with PBS prior to dissociation by a cell scrapper in 0.5 mM EDTA. 
The cell suspensions were transferred into pre-chilled 15 ml falcon tubes and pelleted 
by centrifugation at 3,000 g for 5 min at 4˚C. The supernatant was discarded and the 
cell pellet was resuspended in 1ml of M-PER® mammalian protein extraction reagent 
(PIERCE). The mixture was then mixed at 100 rpm, RT for 10-15 min, followed by 
centrifuging at 14,000g for 20 min at 4˚C. The resulting supernatant was retained and 
purified by µMACs HA tagged protein isolation kit. The purified sample was stored at 
-80˚C until analysis.  
Half of the sample was resolved on a 10% SDS gel alongside PageRulerTM plus 
prestained protein ladder. The gel was then fixed in gel fixing solution (isopropanol: 
dH2O: acetic acid, 25: 65: 10) for 30min before treating with Amplify fluorographic 
reagent for 20 min. Subsequently, the gel was dried under vacuum at 80˚C for 40 min 
and the dried gel was exposed to HyperfilmTM MP at -80˚C for 6 weeks before 
developing. The remaining half of the sample was also run on a 10% SDS gel with 
protein ladder. Similar to section 4.2.2, the sample proteins were transferred to a PVDF 
membrane. The membrane was then blocked by 5% non-fat milk in PBS/0.1% 
Tween-20 for 1 hour. The membrane was incubated with purified mouse antibody 
mono HA.11 (1 in 1000 dilution) in PBS/0.1% Tween-20 2% non-fat milk overnight at 
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4˚C. Followed by washing with PBS/0.1% Tween-20 for 4×15min, the membrane was 
probed with sheep anti-mouse IgG-horseradish peroxidise (1 in 1000 dilution) in 
PBS/0.1% Tween-20 2% non-fat milk. Visualization of the sample proteins was carried 
out by ECL western blotting detection reagents after washing with PBS/0.1% 
Tween-20. 
 
6.3 Results 
6.3.1 Generation of wild type and C-terminal cysteine mutant 
hPAR1eYFP constructs and eYFP-HA11 construct  
Three C-terminal cysteine mutant hPAR1eYFP DNAs were generated by site-directed 
mutagenesis: hPAR1C387AeYFP, hPAR1C388AeYFP and hPAR1C387AC388AeYFP. 
eYFP-HA11 in pcDNA3.1 was also generated. All the constructs were verified by 
automated DNA sequencing (MWG), and the sample containing the correct insert 
sequence was selected for each mutant. 
 
6.3.2 Generation of wild type, C-terminal cysteine mutant hPAR1eYFP 
and eYFP-HA11 permanently expressing cell lines 
Both wild type and mutant hPAR1eYFP stably expressing cell lines were successfully 
generated by single cell cloning as well as eYPF-HA11. The FACS analysis is shown 
in Figure 6.3.1. All the transfected cell lines display a clear rightward shift in 
fluorescence level against parental KNRK cells. The FACS traces of 
hPAR1C387AeYFP and hPAR1C388AeYFP match that of wt-hPAR1eYFP, however, 
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hPAR1C387AC388AeYFP displayed a smaller rightward shift than the others.  
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3.1, FACS traces of hPAR1eYFP receptors cell surface expression. 
Parental KNRK cell line is shown as solid purple with the transfected cell lines shown 
in different colours. The histogram is a representative of at least 3 experiments. 
 
 
6.3.3 C-terminal cysteines affect receptor palmitoylation  
To ascertain whether hPAR1 is palmitoylated on C387 and C388, eYFP-HA11, 
wt-hPAR1eYFP, hPAR1C387AeYFP, hPAR1C388AeYFP and 
hPAR1C387AC388AeYFP cell lines were labelled with [3H] palmitate prior to 
immunoprecipitation of HA11 epitope-tagged receptors. More 
hPAR1C387AC388AeYFP cells were used to gain the same receptor concentration as 
the other hPAR1eYFP cell lines (assessed by western blot analysis, data not shown).  
Autoradiographical and western blot for [3H] palmitate labelled cell lines are shown in 
KNRK 
WT-eYFP 
C387AeYFP 
C388AeYFP 
C387AC388AeYFP 
eYFP-HA11 
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Figure 6.3.2., there is a band at ~150 kDa in the eYFP-HA11 lane. Similar bands are 
also shown in the wt-hPAR1eYFP, hPAR1C387AeYFP and hPAR1C388AeYFP lanes, 
but a lot stronger in the former two lanes. It can be seen that a spread of bands appear 
from 65 to 100 kDa in wt-hPAR1eYFP, hPAR1C387AeYFP and hPAR1C388AeYFP 
lanes, however, hPAR1C387AC388AeYFP displayed no observable radiation signal 
(Fig 6.3.2a). The western blot (Figure 6.3.2b) shows multiple bands ranging from 65 to 
150 kDa as well as bands at ~27, 28, 29, 36 and 42 kDa for wt-hPAR1eYFP, 
hPAR1C387AeYFP, hPAR1C388AeYFP and hPAR1C387AC388AeYFP lanes, however, 
the banding pattern of hPAR1C387AC388AeYFP is much weaker. In the eYFP-HA11 
lane, there are just two detectable bands at 27 and 40 kDa. 
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Figure 6.3.2, Incorporation of [3H] palmitic acid. a) EV, wild type and mutant 
hPAR1 receptors each labelled with 1mCi [3H] palmitic acid for 4 hours and 
HA11-epitope immunoprecipitated run on a 10% SDS-PAGE. Gel dried and exposed 
to X-ray film at -80˚C for 6 weeks. b) a portion of the same samples were analysed on 
western blot. DMeYFP stands for double mutant, namely hPAR1C387AC388A eYFP. 
 
 
 
a) 
eYFP 
HA11 
WT 
eYFP 
C387A 
eYFP 
C388A 
eYFP 
DM 
eYFP 
250 kDa 
72 kDa 
28 kDa 
150 kDa 
100 kDa 
55 kDa 
36 kDa 
b) 
250 kDa 
72 kDa 
28 kDa 
150 kDa 
100 kDa 
55 kDa 
36 kDa 
Monomer 
Dimer 
Monomer 
Dimer 
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6.4 Discussion  
The results in this chapter suggest that hPAR1 is palmitoylated. wt-hPAR1eYFP, 
hPAR1C387AeYFP and hPAR1C388AeYFP all have shown the incorporation of [3H] 
palmitic acid, thus suggesting the three hPAR1 receptors undergo palmitoylation (Fig 
6.3.2). hPAR1C388AeYFP shows a weaker radiation signal than the other two cell 
lines, and hPAR1C387AC388AeYFP has no signal at all suggesting no palmitoylation. 
It may imply that C388 is a primary palmitoylation site and C387 is minor 
palmitoylation site, one cysteine is sufficient to keep the receptor palmitoylation. 
However, despite loading more proteins, the bands for hPAR1C387AC388AeYFP are 
not as dark as the other samples in this experiment, suggesting that the lack of [3H] 
palmitate visualised is caused by the insufficient protein amount (Figure 6.3.2b).  
hPAR1 is known to be heavily glycosylated explaining the smear of multiple bands 
seen in the western blot. Similar banding patterns have been seen in the glycosylation 
study of hPAR1 and the glycosylation and palmitoylation study of hPAR2 (Compton et 
al., 2002, Botham, 2007, Xiao, 2008). According to the size of hPAR1-eYFP 
(hPAR1=47kDa, eYFP=27kDa, 74kDa in total), the banding pattern between 65 kDa 
and 100 kDa would indicate the hPAR1-eYFP monomer and the bands at ~150 kDa are 
possibly as a result of hPAR1 dimerization. The multiple bands on the bottom half of 
the immunoblot in all four hPAR1 lanes could be due to the protein degradation or 
contamination during immunoprecipitation. The band located at ~150 kDa in the 
eYPF-HA11 lane of the autoradiographic blot does not represent in the 
immunoblotting. It suggests the band is caused by the contamination or spillover of the 
sample in the adjacent lane, and eYPF-HA11 is not palmitoylated, thus would not 
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affect the radiation signal in the hPAR1 samples.  
This traditional protein palmitoylation assay is time consuming and takes at least 8 
weeks to finish one experiment. There is a new method to purify and identify 
palmitoylated proteins based on an acyl-biotinyl exchange published recently (Wan et 
al., 2007). In this 3 step protocol, free thiols are blocked by N-ethylmaleimide (NEM), 
and then the Cys-palmitoyl thioester linkage is cleaved by hydroxylamine treatment, 
resulting in the release of palmitoyl moieties and the restore of cysteines/thiols (Wan et 
al., 2007). The newly exposed thiols are subsequently labelled with biotin-HPDP post 
via biotinylation (Wan et al., 2007). The biotinylated proteins are purified using 
agarose beads and analysed. If time had permitted, it would have been useful to repeat 
the palmitoylation studies using this technique. 
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7 General discussion 
The major hypothesis of this thesis was that “The hPAR1 putative palmitoylation 
sites—C-terminal cysteines located at 387and 388 regulate receptor function”. The 
major findings in this research supporting this hypothesis are outlined below: 
1) Either of C387 and C388 is required for the optimal cell surface expression of 
hPAR1. Loss of both cysteines caused a significant decrease in hPAR1 cell surface 
expression. 
2) Either of C387 and C388 is required for the optimal agonist triggered calcium 
signalling (hPAR1-Gq coupling). Loss of both cysteines led to the complete ablation 
of agonist triggered calcium signalling. 
3) C387 and C388 do not affect thrombin triggered receptor internalisation, however, 
in our experiments, wt-hPAR1 does not internalise in response to TFLLR, but the 
mutant cell lines all internalise with TFLLR in a similar way. 
4) Loss of both C387 and C388 in hPAR1 led to the failure in agonist triggered 
ERK1/2 activation. 
Taken together, the findings in this thesis clearly show that cysteines located at 387 and 
388 play an important role in regulating the cell surface expression and the 
downstream signalling of hPAR1. 
Despite nearly all GPCRs being palmitoylated at cysteines present in the C-terminal 
tail, previous studies have suggested that the influence of palmitoylation depends on 
the receptor subtype. The observation also applies to the PAR family. Wt-hPAR2 has a 
putative palmitoylation site on the C-terminal (cysteine361). Palmitoylation-deficient 
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hPAR2 has an increased cell surface expression, decreased calcium signalling triggered 
by trypsin and PAR2AP via Gq protein coupling, and an increased agonist stimulated 
ERK1/2 activation via Gi protein coupling, suggesting that palmitoylation would 
switch the coupling of the G protein. In contrast, palmitoylation-deficient hPAR1 
showed a decreased cell surface expression, and a complete shutoff of calcium 
signalling and ERK1/2 activation induced by thrombin and PAR1AP implying the 
importance of palmitoylation in hPAR1-G protein coupling. Interestingly, similar to 
hPAR1, wt-hPAR2 has also been shown not to internalise in response to its AP and 
internalises slower than palmitoylation-less mutant following proteinase agonist 
activation. In addition, hPAR2AP stimulation failed to induce any alteration in [3H] 
palmitate incorporation with wt-hPAR2, suggesting that wt-hPAR2 did not undergo 
depalmitoylation after hPAR2-AP activation.  
Palmitoylation allows hPAR1 to adopt a conformation that prevents phosphorylation by 
concealing the phosphorylation sites from GRKs. Upon agonist activation, the 
palmitoylated receptor would depalmitoylate, and thus exposes the phosphorylation 
sites to GRKs, resulting in the receptor phosphorylation, desensitisation and β-arrestin 
binding. Subsequently, the receptor internalisation occurs. TFLLR activation may be 
incapable of triggering hPAR1 depalmitoylation like hPAR2, and thus fail to expose the 
phosphorylation sites, in turn, the receptor can not be phosphorylated and the 
internalisation can not take place. However, the failure in receptor phosphorylation 
would cause the prolonged downstream signalling because hPAR1 is desensitised by 
rapid phosphorylation. It is obviously inconsistent with our observations in hPAR1 
triggered calcium signalling and ERK1/2 signalling in response to TFLLR. However, 
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the study by Chen et al revealed that β-arrestins were able to bind and desensitise the 
activated PAR1 independent of receptor phosphorylation (Chen et al., 2004). β-arrestins 
have also been shown not to be involved in PAR1 internalisation (Paing et al., 2002). 
Consequently, TFLLR evoked calcium signalling and ERK1/2 signalling of hPAR1 
would be terminated by β-arrestin binding without the receptor phosphorylation. It also 
implies that receptor depalmitoylation/phosphorylation is required for hPAR1 
internalisation. Thrombin activation would be sufficient to induce hPAR1 
depalmitoylation and then phosphorylation, the receptor internalisation subsequently 
occurs. Nevertheless, TFLLR activation would be unable to elicit hPAR1 
depalmitoylation and thus inhibit the receptor phosphorylation and internalisation.  
hPAR1 lacking palmitoylation would be highly phosphorylated under basal conditions 
and behave as a constitutively desensitised/internalised receptor, owing to the 
increased accessibility of phosphorylation sites which were hidden by palmitoylation 
to GRKs. As a result, hPAR1 is unable to couple to G proteins to trigger any 
downstream signalling pathways. hPAR1 requires an intracellular network so-called 
7-8-1 activation mechanism which is formed by the motif on the 7th transmembrane 
helix, intracellular 8th helix and intracellular loop 1 in coupling to Gq protein. The 
mechanism may also be essential for coupling of hPAR1 to other G protein subtypes. 
The intracellular 8th helix of hPAR1 terminates with cysteines 387 and 388. 
Accordingly, loss of palmitoylation would destroy the 8th helix, in turn the 7-8-1 
connection. Palmitoylation-deficient hPAR1 failed to couple to G proteins and trigger 
downstream signalling pathway. Additionally, alanine was chosen as an amino acid 
substitution for cysteine because they are structurally similar with the thiol group of 
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cysteine being replaced with a methyl group in alanine. This substitution should cause 
minimal disruption to the structure of the protein. Nonetheless, it is notable that all the 
deductions based on that the replacement of cysteines by alanines has no affect the 
hPAR1 protein structure. The potential conformational change caused by the alanine 
replacement may leave the tethered ligand and hPAR1-AP incapable of correctly 
binding to the ligand binding site in ECL2. 
PAR1 as described above regulates many physiological processes and participates in a 
variety of disease states including thrombosis, inflammation of cardiovascular, 
respiratory and gastrointestinal systems, neurodegenerative disorders and cancer, thus 
represents an attractive target for therapeutic drug development. Actually, substantial 
success has been achieved to develop PAR1 inhibitors. Several PAR1 antagonists have 
been developed for pharmaceutical use in humans and some of them are currently in 
the phase II&III clinical trails (Oestreich, 2009, Serebruany et al., 2009, 
Chackalamannil et al., 2005). A number of PAR1 functions including receptor 
expression, downstream signalling and receptor internalisation are dynamically 
regulated by palmitoylation. Therefore, the palmitoylation sites in the C-terminal of 
PAR1 may provide an alternative target of PAR1 drug development. 
Future work 
Two more hPAR1 [3H] palmitate incorporation experiments are needed to be carried 
out in order to confirm whether C387 and C388 are hPAR1 palmitoylation sites. If 
hPAR1C387AC388A is highly phosphorylated and replacement of either cysteines 
would restore the receptor palmitoylation, [32P] phosphorylation assay would be 
utilized to assess the receptor phosphorylation level under basal conditions. 
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hPAR1C387A and hPAR1C388A are expected to have a similar phosphorylation level 
with wt-hPAR1, and hPAR1C387AC388A are expected to show a strong [32P] 
incorporation. hPAR1S391Z which lacks the major phosphorylation site signalled well 
in calcium mobilization but can not shut down properly (data not shown). Thus, it 
leads to a hypothesis that the additional mutation of hPAR1 phosphorylation site 
(hPAR1C387Z) can restore cell surface expression and be able to mediate intracellular 
calcium mobilization or ERK1/2 activation, but can not desensitised appropriately. 
However, in terms of PAR1 7-8-1 activation mechanism, hPAR1C387Z is incapable of 
triggering any downstream signalling pathways. It would be interesting to complete 
these investigations. 
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Appendix: hPAR1eYFP DNA sequence and Protein sequence 
 
ATGCCGAGATCGTGCTGCAGCCGCTCGGGGGCCCTGTTGCTGGCCTTACTGCTTCAGGC
CTCCATGGAAGTGCGTGGTGACTACAAGGACGACGACGACCGCAGGCCAGAATCAAAA
GCAACAAATGCCACCTTAGATCCCCGGTCATTTCTTCTCAGGAACCCCAATGATAAATAT
GAACCATTTTGGGAGGATGAGGAGAAAAATGAAAGTGGGTTAACTGAATACAGATTAG
TCTCCATCAATAAAAGCAGTCCTCTTCAAAAACAACTTCCTGCATTCATCTCAGAAGATG
CCTCCGGATATTTGACCAGCTCCTGGCTGACACTCTTTGTCCCATCTGTGTACACCGGAG
TGTTTGTAGTCAGCCTCCCACTAAACATCATGGCCATCGTTGTGTTCATCCTGAAAATGA
AGGTCAAGAAGCCGGCGGTGGTGTACATGCTGCACCTGGCCACGGCAGATGTGCTGTT
TGTGTCTGTGCTCCCCTTTAAGATCAGCTATTACTTTTCCGGCAGTGATTGGCAGTTTGG
GTCTGAATTGTGTCGCTTCGTCACTGCAGCATTTTACTGTAACATGTACGCCTCTATCTTG
CTCATGACAGTCATAAGCATTGACCGGTTTCTGGCTGTGGTGTATCCCATGCAGTTCCTC
TCCTGGCGTACTCTGGGAAGGGCTTCCTTCACTTGTCTGGCCATCTGGGCTTTGGCCATC
GCAGGGGTAGTGCCTCTGCTCCTCAAGGAGCAAACCATCCAGGTGCCCGGGCTCAACA
TCACTACCTGTCATGATGTGCTCAATGAAACCCTGCTCGAAGGCTACTATGCCTACTACT
TCTCAGCCTTCTCTGCTGTCTTCTTTTTTGTGCCGCTGATCATTTCCA 
CGGTCTGTTATGTGTCTATCATTCGATGTCTTAGCTCTTCCGCAGTTGCCAACCGCAGCA
AGAAGTCCCGGGCTTTGTTCCTGTCAGCTGCTGTTTTCTGCATCTTCATCATTTGCTTCG
GACCCACAAACGTCCTCCTGATTGCGCATTACTCATTCCTTTCTCACACTTCCACCACAG
AGGCTGCCTACTTTGCCTACCTCCTCTGTGTCTGTGTCAGCAGCATAAGCTGCTGCATCG
ACCCCCTAATTTACTATTACGCTTCCTCTGAGTGCCAGAGGTACGTCTACAGTATCTTATG
CTGCAAAGAAAGTTCCGATCCCAGCAGTTATAACAGCAGTGGGCAGTTGATGGCAAGT
AAAATGGATACCTGCTCTAGTAACCTGAATAACAGCATATACAAAAAGCTGTTAACTTAT
CCCTATGATGTTCCCGATTATGCCATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGT
GGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCC
GGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCA
CCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCTTCGGCTACGGCCTGCA
GTGCTTCGCCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGC
CCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGAC
CCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGG
CATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAAC
AGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCA
AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAA
CACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCTACCAGT
CCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGT
GACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAAGGATCCGAGCTC
GGTACCAAGCTTAAGTTTAAACCCGCTGATCAGCCTCGACTGTGC 
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MPRSCCSRSGALLLALLLQASMEVRGDYKDDDDRRPESKATNATLDPRSFLLRNPNDKYE
PFWEDEEKNESGLTEYRLVSINKSSPLQKQLPAFISEDASGYLTSSWLTLFVPSVYTGVFVVS
LPLNIMAIVVFILKMKVKKPAVVYMLHLATADVLFVSVLPFKISYYFSGSDWQFGSELCRFV
TAAFYCNMYASILLMTVISIDRFLAVVYPMQFLSWRTLGRASFTCLAIWALAIAGVVPLLLK
EQTIQVPGLNITTCHDVLNETLLEGYYAYYFSAFSAVFFFVPLIISTVCYVSIIRCLSSSAVANR
SKKSRALFLSAAVFCIFIICFGPTNVLLIAHYSFLSHTSTTEAAYFAYLLCVCVSSISCCIDPLIY
YYASSECQRYVYSILCCKESSDPSSYNSSGQLMASKMDTCSSNLNNSIYKKLLTYPYDVPD
YAMVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWP
TLVTTFGYGLQCFARYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDT
LVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLA
DHYQQNTPIGDGPVLLPDNHYLSYQSALSKDPNEKRDHMVLLEFVTAAGITLGMDELYK. 
 
 
Blue: POMC 
Pink: M1 epitope  
Black: hPAR1 sequence 
Grey: HA11 epitope 
Red: eYFP sequence 
 
